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Toluene Diisocyanate Reference Exposure Levels 
(2,4- and 2,6-Toluene diisocyanate, 1,3-Diisocyanatomethylbenzene, 
Methylphenylene isocyanate, Tolylene diisocyanate) 
CAS: 26471-62-5 (mixed toluene diisocyanate isomers) 
1. Summary 
The Office of Environmental Health Hazard Assessment (OEHHA) is required to 
develop guidelines for conducting health risk assessments under the Air Toxics 
Hot Spots Program (Health and Safety Code Section 44360 (b) (2)).  OEHHA 
developed a Technical Support Document (TSD) in response to this statutory 
requirement that describes acute, 8 hour and chronic RELs and was adopted in 
December 2008.  The TSD presents methodology for deriving Reference 
Exposure Levels.  In particular, the methodology explicitly considers possible 
differential effects on the health of infants, children and other sensitive 
subpopulations, in accordance with the mandate of the Children’s Environmental 
Health Protection Act (Senate Bill 25, Escutia, chapter 731, statutes of 1999, 
Health and Safety Code Sections 39669.5 et seq.).  These guidelines have been 
used to develop the following RELs for toluene diisocyanate: this document will 
be added to Appendix D of the TSD. 
Exposure to diisocyanates, including toluene diisocyanate, has been found to 
cause adverse effects to the respiratory system in both animals and humans. 
These effects include acute impacts such as sensory irritation and the induction 
of asthma in sensitive subjects.  Chronic exposure can result in sensitization and 
long-term decrements in lung function without evidence of sensitization.  Once 
asthma has been induced, triggering of attacks can occur following very low 
exposures (≤1 to 10 ppb) to diisocyanates.  Literature summarized and 
referenced in this document covers the relevant published literature for toluene 
diisocyanate through Spring 2014. 
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1.1.  Toluene 
Reference exposure level 
Critical effect(s) 
Hazard index target(s) 
0.7 µg/m
3 (0.1 ppb) 
Asthmatic response in non-sensitized 
humans with asthma 
Respiratory system 
1.2.  Toluene 
Reference exposure level	  0.008 µg/m
3 (0.001 ppb) 
Critical effect(s)	  Accelerated decline in lung function; TDI-
induced sensitization 
Hazard index target(s)	  Respiratory system 
1.3.  Toluene 
Reference exposure level	  0.008 µg/m
3 (0.001 ppb) 
Critical effect(s)	  Accelerated decline in lung function; TDI-
induced sensitization 
Hazard index target(s)	  Respiratory system 
2. Physical & Chemical Properties (HSDB, 2013) 
TDI Isomer  CAS  Vapor pressure 
Toluene diisocyanate 
(mixed isomers) 
26471-62-5  0.023 mm Hg 25°C 
2,4-toluene diisocyanate  584-84-9  0.008 mm Hg 25°C 
2,6-toluene diisocyanate  91-08-7  0.021 mm Hg 25°C 
Description	  Clear colorless to pale yellow liquid 
Molecular formula	  C9H6N2O2 
Molecular weight	  174.16 g/mol 
Density	  1.22 g/cm
3 (25°C) 
Boiling point	  251°C (mixed isomers) 
Melting point	  11-14°C (mixed isomers) 
Odor threshold	  >20 to 50 ppb (Henschler et al., 1962); 
pungent odor 
Solubility	  Very soluble in acetone and benzene. 
Water solubility at 25°C, 0.038 g/L for 2,4­
TDI; 2,6-TDI decomposes in water 
Conversion factor	  7.1 mg/m
3 = 1 ppm @ 25 C 
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3. Major Uses and Sources 
Toluene diisocyanate (TDI) is used in adhesives, coatings, elastomers, and 
polyurethane foams.  During its production and use, it may be released to the 
environment by volatilization and through various waste streams.  Commercial 
TDI is an isomeric mixture typically comprising 80% 2,4-toluene diisocyanate and 
20% 2,6-toluene diisocyanate.  Both isomeric forms are listed as Toxic Air 
Contaminants (TAC) (OEHHA, 2008).  U.S. EPA (2010) reported in their IUR 
(Inventory Update Reporting) that the aggregated national production volume of 
TDI was 1 billion pounds or greater in 2006.  Reported release of TDI to the air in 
California in 2008 was at the rate of 0.28 tons/year (CARB, 2011).  Given the 
vapor pressures of the constituent isomers, toluene diisocyanate in air will exist 
solely as a vapor.  Vapor-phase TDI may be degraded in the atmosphere by 
reaction with photochemically-produced hydroxyl radicals with an estimated half-
life of 2.7 days for the mixed isomers, 1.7 days for 2,4-TDI, and 2.5 days for the 
2,6-isomer.  Rapid degradation of low levels of TDI in water is expected to 
preclude leaching or adsorption to solids in moist soils, as well as 
bioconcentration in aquatic organisms.  However, airborne TDI does not appear 
to react significantly with atmospheric water vapor (Tury et al., 2003). 
Occupational exposure to TDI may occur through inhalation and dermal contact 
during its production or use.  The general population may be exposed to TDI via 
emissions from facilities that use TDI and use of consumer products containing 
this compound (Darcey et al., 2002; Krone and Klingner, 2005).  These may 
include products in which the monomeric or prepolymeric form of TDI is present 
by design, such as in paints and varnishes.  
However, TDI manufactured as a prepolymer (Figure 1) is much less volatile but 
still retains a high level of reactivity.  Thus, while the potential for vapor exposure 
is reduced with the prepolymer, exposure to aerosols generated during use 
remains a possibility, as does the potential for pulmonary effects. 
Figure 1.  Formation of TDI Prepolymer 
In an attempt to minimize potentially harmful exposures, TDI has been replaced 
in many applications, especially consumer products, by other less volatile and 
reactive compounds such as methylene diphenyl diisocyanate (MDI) and 
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hexamethylene diisocyanate (HDI), so direct handling of TDI containing materials 
by consumers is less frequent.  TDI and MDI are the most commonly used 
diisocyanates for the manufacture of polyurethanes.  About 95% of all 
polyurethanes are based on TDI and MDI (Vandenplas et al., 1993b).  HDI is 
another commercially important diisocyanate used principally as a hardener in 
spray paints and is listed on the California Toxic Air Contaminant list 
(Vandenplas et al., 1993b; CARB, 2010).  Other diisocyanates available include 
naphthylene diisocyanate (NDI), isophorone diisocyanate (IPDI) and 
dicyclohexylmethane diisocyanate or hydrogenated MDI (HMDI) but their use is 
limited to more specialized applications.  All of these diisocyanates are also 
known to cause asthma in occupational settings. 
4. Metabolism 
TDI is characterized by the N=C=O group which contains two double bonds and
 
exhibits strong chemical reactivity (Raulf-Heimsoth and Baur, 1998).  Animal 

inhalation studies with 
14C-labeled TDI showed that TDI is mainly absorbed in the
 
upper airways (Kennedy et al., 1989).  Inhaled TDI was found in the epithelium
 
and the subepithelial level from the nose down to the terminal bronchioles.  The
 
uptake of TDI into the blood is linear during exposure at concentrations ranging
 
from 0.05 to 146 ppb.
 
Based on experiments in rats exposed to 2,4-TDI by inhalation, oral or iv routes, 

the metabolic scheme in Figure 2 was proposed by Timchalk et al. (1994).  As 

with other isocyanates, TDI can readily react with hydroxyl, sulfhydryl and amine
 
groups on macromolecules including hemoglobin, glutathione, laminin, serum
 
albumin, and tubulin (Brown and Burkert, 2002).  In the gut, hydrolysis of TDI 

generates toluene-2,4-diamine (TDA), a carcinogen.  Free TDA may be absorbed
 
and be further metabolized, or may react with TDI to form polyurea polymers that
 
are poorly absorbed and thus eliminated in the feces.  In experimental 

administration by the oral route, 12-20% of the dose was absorbed, while by the
 
inhalation route, essentially all the TDI was absorbed and retained (Timchalk et 

al., 1994).  Inhalation exposure leads preferentially to the formation of TDI
 
conjugates and little or no measurable TDA (Timchalk et al., 1994; Lindberg et 

al., 2011).  These route-dependent differences in fate are posited to explain the
 
observed carcinogenicity of TDI by the oral (with conversion to TDA) but not the
 
inhalation route in experimental animals (Collins, 2002).  Exposure to TDI also 

occurs via dermal absorption and can lead to both dermal and pulmonary
 
hypersensitivity (Karol et al., 1981).  The metabolic fate of TDI following dermal 

exposure is expected to be similar to that following inhalation.
 
In occupational studies, a correlation between airborne exposure to TDI and
 
urinary TDI metabolite concentrations has been found in workers (Geens et al., 

2012).  Urinary samples were hydrolyzed with sodium hydroxide to release the
 
TDI-related diamines 2,4- and 2,6-TDA and then quantified as total TDA.  

Through regression analysis, a post-shift minus pre-shift TDA urine concentration
 
of 18.12 µg/L corresponded to an airborne TDI concentration of 5 ppb (37 µg/m
3).
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A combined half-life of TDA in urine was 1.1 days, indicating that TDI metabolites 
may accumulate in the body of workers during the workweek. 
Figure 2. Metabolic Scheme for TDI in Rat (Timchalk et al., 1994) 
5. Acute Toxicity of Toluene Diisocyanate 
The main effect of acute exposure to TDI in previously non-exposed individuals is 
sensory irritation.  In experimental animals, this has been measured as 
respiratory rate depression.  However, TDI may also act as a pulmonary irritant 
resulting in increased respiratory rate (Castranova et al., 2002).  Dermal 
exposure and/or inhalation exposures to acutely high levels or long-term lower 
levels of TDI may result in allergic sensitization.  If acute exposure is severe 
enough, a condition known as reactive airways dysfunction syndrome (RADS) 
may occur that may persist for years.  Subsequent exposure to low-level TDI or 
other irritants in these individuals result in pulmonary symptoms including 
bronchial hyperresponsiveness and airflow obstruction.  Asthmatic cross 
reactivity between different isocyanates has been documented.  Innocenti et al. 
(1988) found that nearly 50% of subjects with asthma induced by TDI also 
exhibited asthmatic reactions to MDI, which they were never exposed to at work. 
In another study, of 13 workers exclusively exposed to MDI, four also reacted to 
TDI (O'Brien et al., 1979a).  In six workers with IgE-mediated sensitization to 
isocyanates, radioallergosorbent test (RAST) and/or skin-test investigations 
revealed the presence of IgE antibodies reacting specifically with isocyanates 
conjugated with human serum albumin (HSA); these isocyanates included those 
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to which workers were exposed as well as other isocyanates to which they had 
not been exposed (Baur, 1983).  These results indicate the predominance of 
closely related antigenic determinants in HSA conjugated with different 
isocyanates.  The common antibody-binding regions are recognized to different 
extents by antibodies of clinically sensitized workers, indicating individual 
differences in specificities and avidities of antibody populations. 
There is evidence that prepolymers of isocyanates, including TDI prepolymers, 
can themselves cause occupational asthma.  A case study showed that specific 
inhalation challenges with a prepolymer of TDI elicited asthmatic reactions in two 
subjects who were not affected by challenge with the monomer of TDI 
(Vandenplas et al., 1992). 
5.1.  Acute Toxicity to Adult Humans 
Acute respiratory exposures to TDI are typically reported in occupational settings 
with responses ranging from upper airway irritation to toxic bronchitis (Ott et al., 
2003).  Eye, nose and throat irritation are often the first manifestations of acute 
high exposure to TDI, with dry cough, and chest pain and tightness ensuing. 
Patchy infiltrates may be seen on chest X-rays, and the clinical picture may 
approximate bronchitis, bronchiolitis, bronchial asthma, or pneumonitis (Peters 
and Wegman, 1975).  While less likely than with chronic exposures, high acute 
exposure may result in allergic sensitization.  In these cases a subsequent acute 
inhalation exposure, often considerably below the odor and sensory irritation 
threshold (i.e., <5-20 ppb), may provoke a potentially life-threatening pulmonary 
hypersensitivity response. 
5.1.1.  Dose-Response Chamber Studies in Humans 
Henschler et al. (1962) conducted one of the only controlled human exposure 
studies with exposure concentrations of TDI considerably above 20 ppb.  In the 
German article (translated into English by OEHHA), six healthy men were 
exposed to various concentrations of TDI 65/35 (2,4-TDI and 2,6-TDI, 
respectively) and to the pure isomers for 30 min in an exposure chamber.  The 
subjects were only exposed to one concentration of TDI per day, which was 
randomly selected.  At 0.01 and 0.02 ppm (10 and 20 ppb) neither odor nor other 
sensory symptoms were perceived.  At 0.05 ppm, the odor of TDI was perceived 
immediately upon entering the chamber, but was not noticeable by the men after 
4-9 min of exposure.  Three of 6 subjects noted conjunctiva irritation by 15 min of 
exposure, which was described as “tear stimulus, but without tearing”. 
At 0.075 ppm TDI 65/35, the odor was stronger and took longer to become 
unnoticeable (12-14 min).  A light burning sensation of the eye without tearing 
was experienced in the subjects after 1-6 min of exposure.  When asked to 
breathe deeply, all felt a tingling or slight stinging sensation in the nose. 
Exposure to 0.1 ppm produced more severe eye and nose irritation described as 
resembling a cold.  Odor disappeared after 12-15 minutes. 
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At 0.5 ppm, lacrimation was elicited in all subjects, but the eye irritation was still 
considered bearable.  A strong stinging sensation and greater secretion from the 
nose were noted.  The throat was described as scratchy or burning, but without 
coughing.  Two subjects were exposed to 1.3 ppm TDI 65/35 for 10 min resulting 
in heavy eye tearing, eye reddening and eyelid closure.  Several hours after 
exposure, significant catarrhal symptoms (mucous membrane inflammation) of 
the respiratory tract appeared with coughing. 
Henschler et al. (1962) also exposed subjects to pure 2,4-TDI and 2,6-TDI 
individually.  Exposure to 0.02 ppm 2,4-TDI did not result in sensory symptoms, 
but a weak odor was noted at 0.05 ppm.  No eye irritation was noted.  Irritation of 
the conjunctiva and nose occurred at 0.08 ppm, which was significantly stronger 
with exposure to 0.1 ppm.  Eye irritation occurred in 2 out of 5 subjects at 0.2 
ppm, while 0.5 ppm caused tearing, which was described as piercing and 
annoying in all subjects.  Exposure to 2,6-TDI was described as having similar 
sensory effects as that produced by 65/35 TDI, but was considered slightly 
stronger than the same concentration of 2,4-TDI.  At 0.5 ppm 2,6-TDI, the 
subjects could not differentiate from the effects produced by 2,4-TDI at the same 
concentration. 
The threshold for odor recognition reported by Henschler et al. (1962) is 
supported by numerous reports of exposures of 5-20 ppb resulting in no 
noticeable odor.  Other acute studies that were primarily conducted to assess or 
confirm TDI-sensitization in workers also found no sensory irritation in normal 
humans with exposures up to 20 ppb for 30 min or less.  In support of the finding 
of sensory irritation at 50 ppb and above by Henschler et al. is a report by Lee 
and Phoon (1992) in which uncontrolled industrial exposure to a mean 
concentration of 160 ppb TDI (range: 10 to 500 ppb) resulted in eye and 
respiratory system irritation.  Similarly, painters handling polyurethane varnish 
experienced eye, nose and throat irritation with exposure to TDI concentrations 
of 70-170 ppb (Huang et al., 1991). 
5.1.2.  Challenge Studies in Sensitized Workers 
There are numerous reports in the literature in which low acute concentrations of 
TDI were used to study or confirm a diagnosis of probable toluene diisocyanate 
asthma in workers (Chester et al., 1979; Mapp et al., 1986; Moller et al., 1986a; 
Boschetto et al., 1987; Banks et al., 1989; Vogelmeier et al., 1991; Karol et al., 
1994; Pisati et al., 2007).  Concentrations of TDI in these challenge tests usually 
ranged between 5 and 20 ppb with exposure durations of 10 min to several 
hours.  With the exception of a few early reports, concentrations of TDI higher 
than 20 ppb are not used in controlled human studies due to the potential to 
provoke acute allergic sensitization, sensory irritation and respiratory 
inflammation. 
In studies in workers suspected to have TDI-induced asthma, pulmonary 
responses often resulted from exposures below 10 ppb TDI.  The lowest 
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controlled exposure to TDI resulting in an asthmatic response is ≤1 ppb.  Lemiere 
et al. (2002) exposed eight subjects with occupational asthma induced by 
specific diisocyanates (TDI, MDI or HDI) to 1 ppb using a closed circuit 
apparatus.  The authors considered a positive result to be a 20% or greater 
reduction in Forced Expiratory Volume in 1 second (FEV1).  By this criterion 
asthma symptoms were triggered in two of the subjects with a 30 min exposure, 
one to MDI and the other to HDI.  A third subject had asthma symptoms with a 45 
min exposure to TDI.  There was also a significant correlation (Spearman rank 
order test ρ=0.8, P<0.001) between the percentage of maximum decrease in 
FEV1 after exposure to 1 ppb and the increase in sputum neutrophil count, 
indicating inflammatory changes as well. 
In another study of workers suspected to have TDI-induced asthma, 9 out of 63 
subjects responded with a fall in FEV1 of 15% or more following exposure to a 
TDI concentration of ≤1 ppb for 30 min (O'Brien et al., 1979b).  This sensitive 
subgroup of TDI responders also showed a significantly greater increase in 
bronchial reactivity to both histamine and exercise than the TDI-sensitive 
subgroup with asthmatic reactions to TDI concentrations of 2-20 ppm (28 
subjects), and the TDI non-sensitive group (26 subjects). 
5.1.3.  Challenge Studies in Normals and Non-Sensitized Asthmatics 
More pertinent to derivation of an acute REL for TDI, some studies also tested 
pulmonary response in exposed normal and asthmatic subjects with no 
sensitization or history of exposure to isocyanates, in addition to testing the 
pulmonary response in workers with probable TDI sensitization. 
Vogelmeier et al., 1991; and Baur and Colleagues, 1994 
Diisocyanate inhalation tests were performed in exposure chambers on 19 
workers with diisocyanate-induced asthma and on 10 healthy and 15 asthmatic 
volunteers with no previous contact with diisocyanates (Vogelmeier et al., 1991; 
Baur et al., 1994).  The ten healthy individuals had a negative methacholine test 
and were exposed to 20 ppb TDI for 2 hrs.  The 15 patients with asthma had a 
positive methacholine test and were exposed for one hr to 10 ppb TDI, followed 
by a 45 min break, then a one hr exposure to 20 ppb.  Pulmonary function tests 
included airway resistance (Raw), specific airway conductance, FEV1, inspiratory 
vital capacity, total lung capacity.  The pulmonary function test results of 
volunteers without previous contact with diisocyanates were presented by two 
different approaches: Vogelmeier et al. (1991) used a >50% decrease in specific 
airway conductance from the zero value as evidence of a positive airway 
reaction, while Baur et al. (1994) used a 100% increase of airway resistance as 
evidence of a positive airway reaction. 
In the approach used by Vogelmeier et al. (1991), one of 10 normal volunteers 
showed a positive airway reaction (>50% decrease in specific airway 
conductance) to 20 ppb TDI, and one of 15 subjects with asthma had a positive 
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airway reaction to 10 ppb TDI.  With subsequent exposure of the asthmatic 
subjects to 20 ppb for 1 hour, two of the remaining 13 asthmatic subjects had a 
positive reaction to 20 ppb TDI. (Baur et al. (1994) later clarified that the subject 
responding to 10 ppb of TDI and another subject with asthma who refused to 
continue did not undergo the second challenge with 20 ppb TDI).  All the positive 
airway reactions occurred during the first hour after inhalation; late responses 
were not observed.  Vogelmeier et al. concluded that supposedly sub-irritant 
concentrations of TDI may induce a marked airway reaction in healthy volunteers 
and patients with asthma. 
Baur et al. (1994) then presented the Raw results measured by body 
plethysmography on the same subjects.  Using 100% increase in Raw 
(amounting to values of >0.5 kPa/l per second) as evidence of a positive airway 
reaction, none of the 10 healthy controls had an asthmatic response with a two-
hour exposure to 20 ppb TDI.  In contrast, one of 15 asthmatics responded to 10 
ppb with a severe asthmatic reaction.  Another asthmatic subject from the 
remaining group of 13 subjects showed an asthmatic reaction to 20 ppb.  Based 
on these results, Baur et al. presented a different conclusion from Vogelmeier et 
al. (1991).  Baur et al. concluded that the TDI exposures in the TLV range (5 to 
20 ppb) do not change lung function in healthy subjects and only rarely in 
previously unexposed asthmatics, indicating that asthmatic responses in TDI 
challenge tests are not absolutely specific to sensitized individuals. 
Additional details of this study are in Baur (1985), but were unavailable to 
OEHHA.  However, this study was summarized by NRC (2004).  Of the 15 
asthmatic subjects exposed to TDI, five complained of chest tightness, rhinitis, 
cough, dyspnea, throat irritation, and/or headache during exposure.  It was 
unclear from the report what concentration of TDI caused these symptoms. 
Three normal subjects reported eye irritation and/or cough.  Among the 
asthmatics, no decrease in FEV1 <20% was observed, although two showed a 
decrease in FEV1 between 15 and 20%.  Increases in Raw did not correspond 
with decreases in FEV1, and neither parameter could be used as an indication of 
the reported symptom discomfort. 
Fruhmann et al., 1987 
An apparently different group of subjects were examined using similar 
methodology, and was conducted by many of the same researchers in Baur et al. 
(1994) and Vogelmeier et al. (1991).  In this German study by Fruhmann et al. 
(1987), translated into English by OEHHA, 15 healthy and 15 asthmatic subjects 
with no previous contact with diisocyanates were exposed to TDI and airway 
resistance (Raw) recorded periodically by whole body plethysmography.  The 
healthy subjects were chamber-exposed to 20 ppb TDI for 2 hrs, while the 
asthmatic subjects were exposed to 10 ppb TDI for 1 hr, then given a break for 
45 min followed by a 1 hr exposure to 20 ppb TDI.  For healthy subjects, mean 
Raw before and after exposure was 0.12 and 0.17 kPa.s.L
-1, respectively, with no 
individual experiencing an increase in Raw above 0.25 kPa.s.L
-1 .  A normal Raw 
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result was considered to be <0.35 kPa.s.L
-1 .  For the asthmatic subjects, 
significant changes and complaints were recorded in one-third of the subjects, 
although the authors did not specify what these changes and complaints were 
other than presenting the individual Raw results.  Three of the 15 asthmatic 
subjects experienced a maximum Raw value greater than 100 percent of their 
control value taken before exposure.  Raw was recorded during and up to 3 hrs 
post-exposure, but it was not specified exactly when the highest Raw value was 
recorded.  Another five asthmatic subjects had a maximum increased Raw 
between 50-100 percent of their control value, all of which were above 0.35 
kPa.s.L
-1 . 
Chester et al., 1979 
Chester et al. (1979) exposed 40 subjects by facemask to 20 ppb TDI for 20 min 
and then assessed airway response by specific airway resistance (SRaw) at 
regular intervals for up to six hours following exposure.  Twenty of the subjects 
were symptomatic TDI workers and the other subjects were a nonsmoking 
control group without previous TDI exposure consisting of 10 healthy subjects 
and 10 subjects with extrinsic asthma.  The authors defined symptomatic TDI 
workers as those that have experienced bronchoconstriction with occupational 
TDI exposure.  Using an increase in SRaw>50% above baseline resistance as a 
positive response to the TDI challenge, Chester et al. found that 9 of the 20 TDI 
workers were positive responders (one immediate, five dual and three late 
asthmatic reactions).  None of the extrinsic asthmatics or normal subjects 
responded to 20 ppb TDI by an increase in their SRaw greater than 50%.  The 
specific changes in SRaw experienced by the asthmatics and normals were not 
presented by the authors. 
Some control subjects and seven of the non-responding TDI workers were then 
assessed for small airway function by testing for maximum expiratory flow 
volume by breathing air and repeated when breathing helium-oxygen (Chester et 
al., 1979).  Using the criteria of a 40% increase in the volume of isoflow and a 
40% decrease in Forced Expiratory flow at 50%FVC (ΔFEF50) as evidence of 
small airway changes, the authors observed that five of seven “non-responders” 
had reduced lung function.  Of the normal subjects and seven subjects with 
extrinsic asthma examined using these pulmonary function tests, none were 
considered responders by the criteria applied. 
Fabbri et al., 1987 
Fabbri et al. (1987) exposed 6 normal subjects with no previously documented 
asthmatic reaction to TDI to 18 ppb TDI for 30 min.  FEV1 and airway 
responsiveness to methacholine were unaffected by TDI exposure. 
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Moller et al., 1986 
Moller et al. (1986b) exposed 10 subjects with a positive methacholine challenge 
test, but with no apparent previous exposure to TDI, to concentrations of TDI up 
to 20 ppb for 15 min.  A positive methacholine test was considered to be a fall in 
FEV1 of 20% or greater when exposed to a total cumulative dose of <2,000 µg 
methacholine.  No change in FEV1 was observed with exposure to TDI in these 
subjects. 
Mapp et al., 1986 
In addition to exposing a group of 40 sensitized TDI-workers (10 each with 
immediate, dual, late, or no asthmatic reactions after exposure to TDI) to 18 ppb 
TDI for up to 30 min, Mapp et al. (1986) also exposed eight asthmatic subjects 
with no history of sensitization to TDI.  FEV1 was measured immediately before 
and after exposure and then hourly for 8 hrs.  The provocative dose of 
methacholine that had previously caused a decrease in FEV1 of 20% (PD20, the 
dose of methacholine in mg) was also measured.  An asthmatic reaction was 
considered to occur when FEV1 decreased by 20% from baseline, or an increase 
in airway responsiveness occurred when the PD20 FEV1 decreased at least two­
fold.  By this measure, exposure to TDI did not elicit an asthmatic reaction in the 
group of asthmatic subjects not sensitized to TDI.  Although airway 
responsiveness was markedly increased with methacholine challenge in 
asthmatic subjects not sensitized to diisocyanates, the authors found no further 
decrease in FEV1 after TDI inhalation with challenge at the PD20. 
Vandenplas et al., 1999 
Vandenplas et al. (1999) exposed 17 subjects without respiratory symptoms 
(eight smokers and nine nonsmokers) or occupational exposure to diisocyanates 
to ambient air and once to 5 ppb TDI for 6 hrs followed by 20 ppb TDI for 20 min. 
Nonspecific bronchial responsiveness was assessed by inhalation of histamine, 
which was expressed as the concentration of histamine causing a 20% fall in 
FEV1.  Several pulmonary function tests including specific airway conductance 
(sGaw), functional residual capacity (FRC), total lung capacity (TLC), forced vital 
capacity (FVC), FEV1, FEV1/FVC ratio, and maximal expiratory flow at 50% of 
FVC (MEF50%), and at 25% of FVC (MEF25%), were carried out before exposure 
and at every hour during exposure.  Bronchial lavage (BL) and bronchoalveolar 
lavage (BAL) were performed 1 hr after each exposure. 
None of the subjects in the Vandenplas et al. (1999) study experienced 
significant respiratory symptoms in response to the exposures.  Comparison of 
pre- and post-exposure pulmonary function values did not result in significant 
differences.  The pulmonary function tests did find detectable changes in airway 
caliber throughout the exposure period using regression analysis of repeated 
measures.  Compared to ambient air exposure, TDI exposure resulted in a 
modest decrease in sGaw (p=0.053) and in MEF25% (p=0.015).  Multivariate 
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analysis of the time-point differences in sGaw showed that the mean 
concentration of TDI was a significant determinant of the response, while the 
level of nonspecific responsiveness to histamine had a significant effect on 
changes to MEF25% induced by TDI exposure.  The authors suggest these results 
show that TDI could exert an effect on both small and large airways. 
TDI exposure in the Vandenplas et al. (1999) study also resulted in a slight 
increase in BAL albumin level (TDI: 26.4+12.5 vs. air: 21.8+8.6 µg/ml, p=0.044) 
and in BL α2-macroglobulin concentration (TDI: 0.07+0.061 vs. air: 0.05+0.04 
µg/ml, p=0.044).  The authors note that the observed increase in BAL albumin 
content after TDI exposure likely represents indirect evidence of changes in 
permeability of the epithelial barrier and slight leakage of blood plasma 
components into the alveolar compartment.  The increase in BL α2-macroglobulin 
level could reflect a selective increase in epithelial permeability associated with 
local production.  The concentrations of potential indicators of epithelial cell 
dysfunction (secretory component and CC16) and pro-inflammatory cytokines 
(TNF- α, IL-4, IL-5, IL-6 and IL-8) were not significantly altered by TDI exposure, 
suggesting to the authors that the observed TDI-related changes in pulmonary 
function tests were not directly related to airway inflammation. 
A summary of the acute studies presented above is shown in Table 1. 
Appendix D1  12  Toluene Diisocyanate          
     
 
 
   
 
   
 
   
 
   
   
   
 
 
   
   
 
 
 
 
   
     
 
   
   
 
 
   
     
   
 
 
 
   
   
   
   
 
 
   
 
 
       
     
   
 
 
 
 
     
   
   
 
 
 
 
 
   
 
   
 
 
 
 
     
     
   
   
 
 
 
 
 
   
 
 
 
   
   
     
 
 
Public Review Review  July 2014 
Table 1. Summary of Controlled Acute Exposure Studies in Non-Sensitized 
Subjects 
Study  TDI Exposure 
Conditions 
Pulmonary/Sensory Findings 
Henschler  6 subjects, 1  No symptoms at 10 or 20 ppb; 
et al.  exposure/day  increasing sensory irritation with 
(1962)  30 min exposure to: 
10, 20. 50, 75, 100, 
500, and 10 min 
exposure to 1300 ppb 
increasing TDI concentration starting at 
50 ppb and above. 
Vogelmeier  10 normal subjects, 20  Normals: No significant pulmonary 
et al., 1991;  ppb for 2 hrs  decrement; 3 complained of eye irritation 
Baur et al.,  15 asthmatics, 10 ppb  and/or cough 
1994  for 1 hr, 45 min break,  Asthmatics: 1/15 had ≥100% increase in 
then 20 ppb for 1 hr  Raw at 10 ppb; 1/13 had ≥100% 
increase in Raw at 20 ppb; overall, 5 
complained of chest tightness, rhinitis, 
cough, dyspnea, throat irritation, and/or 
headache 
Fruhmann  15 normal subjects, 20  Normals: No significant increase in Raw 
et al., 1987  ppb for 2 hrs  Asthmatics: 3/15 had ≥100% increase in 
15 asthmatics, 10 ppb  Raw; one-third of subjects experienced 
for 1 hr, 45 min break,  significant, but unspecified, changes or 
then 20 ppb for 1 hr  complaints 
Chester et 
al. (1979) 
10 normal subjects 
and 10 asthmatics 
20 ppb for 20 min 
No increase in SRaw greater than 50% 
in any subject 
Fabbri et al. 
(1987) 
6 normal subjects 
18 ppb for 30 min 
No change in FEV1 or airway 
responsiveness to methacholine 
Moller et  10 subjects with  No change in FEV1 observed with 
al., 1986  positive methacholine 
challenge test 
up to 20 ppb for 15 
min 
methacholine challenge after TDI 
exposure 
Mapp et al., 
1986 
8 asthmatic subjects 
18 ppb for 30 min 
No decrease in FEV1 ≥20% observed; 
No decrease in the PD20 FEV1 greater 
than 2-fold with methacholine challenge 
Vandenplas 
et al. 
(1999) 
17 normal subjects 
5 ppb for 6 hrs 
followed by 20 ppb for 
20 min, with 
pulmonary function 
test every hr 
Decreased sGaw (p=0.053) and MEF25% 
(p=0.015) measured by regression 
analysis of repeated measures; 
increased BAL albumin level (p=0.044) 
and BL macroglobulin (p=0.044) 
concentration 
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5.2.  Acute Toxicity to Infants and Children 
No studies were located that examined the effects of acute exposure to TDI in 
children.  However, the effects due to acute TDI exposure may be expected to be 
similar to those reported following acute accidental exposure of school children to 
methylene diphenyl diisocyanate (MDI) (Jan et al., 2008).  In this report, asthma-
like symptoms were observed among 203 schoolchildren following acute 
exposure to MDI and toluene spilled during track paving with polyurethane.  Of 
the exposed children, 70.9% reported headache, 67.5% had persistent cough, 
63.5% had dyspnea, and 62.6% nausea.  Chest discomfort was reported by 
23.6% of the students but chest X-rays were normal.  Bronchodilators were 
administered to 15.8% who experienced wheezing and difficulty breathing. 
Although no measurements of actual air MDI levels were reported, the authors 
observed an inverse linear relationship between the incidence of affected 
students in various classrooms and the distance from the site of MDI spillage (r = 
-0.48, p < 0.05) suggesting a dose-response. 
During follow-up surveillance three days after the incident, the prevalence of 
residual symptoms was cough 30.0%, headache 19.7%, dyspnea 15.3%, sore 
throat 10.3%, and nausea 3.9%.  A positive history of asthma among 10.8% of 
the students was strongly correlated with the incidence of dyspnea (OR 4.09; 
95% CI 1.17-14.32) and an abnormal pulmonary function test (OR 3.84; 95% CI 
1.09-13.5).  However, none of the other symptoms during the episode was 
correlated with either asthma history or abnormal lung function tests.  In addition, 
60.8% of the children without a history of asthma also complained of dyspnea, 
and 16.2% required bronchodilators for symptomatic relief.  Acute exposure to 
high levels of MDI was thus associated with reactive airway dysfunction (RADS) 
among previously unexposed individuals.  The authors did not discuss effects 
seen in exposed adults, so it is unclear if children were more prone to the acute 
effects of MDI than adults.  Also, no apparent follow-up was performed to 
determine if the children had been immunologically sensitized as a result of the 
high acute exposure. 
Krone and associates have postulated that a relationship exists between 
exposure to polyurethane products made from isocyanates and childhood 
asthma (Krone and Klingner, 2005).  Further discussion is presented in Section 
6.2. 
5.3.  Acute Toxicity to Experimental Animals 
The effects on the respiratory tract of a single 4-hour exposure of mice, rats, 
guinea pigs and rabbits to 2, 5 or 10 ppm TDI were reported by Duncan et al. 
(1962).  Two hours following termination of the exposure to 2 ppm, focal 
coagulation necrosis and desquamation of the superficial epithelium lining the 
trachea and the major bronchi were observed.  Occasionally bronchial airways 
were found containing acute inflammatory cells associated with sloughed 
epithelium.  However, by one day following exposure, acute inflammatory 
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exudates were observed in the majority of the major bronchi, along with further 
desquamation of necrotic epithelium.  Fibrinous strands were observed in the 
lumina, and an infiltration of polymorphonuclear leukocytes extended through the 
edematous peribronchiolar connective tissue.  Acute inflammatory cells also 
infiltrated the edematous perivascular spaces of the accompanying vessels.  By 
day four, there were signs of clearing of the inflammatory response and evidence 
of regeneration of tracheal and bronchial epithelium.  By day seven, control and 
exposed animals were not significantly different.  While the effects of exposure to 
2 ppm were largely transient, exposures at 5 and 10 ppm resulted in more severe 
effects that were not completely reversible.  The LOAEL for these effects was 2 
ppm, but a NOAEL was not observed. 
The effects of single, and repeated 3-hour exposures to 2,4-TDI vapor on 
sensory irritation at concentrations ranging from 0.007 to 2 ppm were measured 
as respiratory rate depression and nasal histopathology in mice (Sangha and 
Alarie, 1979).  With single exposures, time-response relationships showed the 
slow development of the respiratory response with exposure duration. 
Concentration-response relationships also showed that the level of the response 
was dependent upon both exposure concentration and duration.  Repeated 
exposures at ≥0.023 ppm resulted in cumulative effects.  Regardless of the TDI 
concentration used, respiratory rates decreased relatively rapidly during the first 
10 minutes of exposure, followed by a more gradual decline.  As shown in Table 
2, depression of the respiratory rate by 50% (RD50) was achieved in 10 min at a 
concentration of 0.813 ppm, in 60 min at 0.386 ppm, but took 180 minutes at 
0.199 ppm. 
Table 2.  Respiratory Depression (RD50) Dependence on Exposure 
Duration 
Exposure Time (min)  10  30  60  120  180  240 
RD50 (ppm)  0.813  0.498  0.386  0.249  0.199  0.199 
Recovery of respiratory rate following cessation of exposure was similarly 
duration dependent, being rapid with short exposures and slow with long 
exposures.  This is in contrast to other sensory irritants such as acrolein, the 
response to which is only concentration dependent and recovery is rapid 
regardless of the exposure duration (Kane and Alarie, 1977).  The slow rate of 
recovery became more evident when 3-hour exposures of 0.023, 0.078, 0.301, 
0.505, 0.82, and 1.18 ppm were repeated on successive days.  On the first day 
of exposure, the drop in respiration rate was similar to that of the single 
exposures: rapid during the first 10 minutes, with a more gradual descent 
thereafter.  However, on subsequent days, the pre-exposure rates were 
progressively lower indicating incomplete recovery from the exposures on 
previous days.  Recovery to baseline required at least five days after the last 
exposure. By contrast, with exposures in the range of 0.007 to 0.018 ppm, there 
were no consistent respiratory responses after the three-hour exposures, nor 
was there the pattern of reduced respiratory rate with repeated exposure. 
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Histopathological evaluation of successive transverse sections of the nasal area 
revealed no lesions following three days of exposure for 3 hours/day to 0.031 
ppm.  However, in mice similarly exposed to 0.25 ppm, damage was consistently 
observed in the most anterior section of the nasal passages and external nares, 
with 25-50% of the mucosa involved including some extension into the 
submucosa.  The lesions were much less pronounced in more distal sections. 
These results suggest that, in addition to the potential for immune 
hypersensitization demonstrated in other studies (Karol et al., 1980), TDI has 
cumulative irritant effects that result from incomplete recovery from previous 
exposures above a certain level in this rodent model.  Both the development of 
and recovery from these effects are slow, possibly consistent with covalent 
modification of receptors as in the reaction of TDI with OH or NH2 groups in 
proteins and/or specific residues on TRPA channels in sensory neurons.  TRPA 
belongs to the family of transient receptor potential (TRP) channels that 
transduce sensory neurons’ response to thermal, mechanical, and specific 
chemical stimuli. 
In guinea pigs, Gagnaire et al. (1988) demonstrated that TDI-induced airway 
hyperresponsiveness to intravenous acetylcholine can occur with continuous 
exposure as short as a single 4 hr exposure to 1.2 ppm.  Similar responses to 
acetylcholine in guinea pigs were seen with TDI exposures to 118 ppb for 48 hr, 
1.08 ppm for 4 hr/day for 2 days, and continuous exposure to 23 ppb for 1 week.  
However, regardless of exposure concentration or duration, TDI did not modify 
the baseline airway resistance (Raw).  The authors concluded the study results 
were consistent with the hypothesis of a cumulative effect of TDI on airway 
hyperresponsiveness. 
It is important to note that the development of pulmonary sensitivity to TDI does 
not require inhalation exposure.  Working with guinea pigs, Karol et al. (1981) 
demonstrated that single dermal exposures to TDI were sufficient to elicit signs of 
significant pulmonary sensitivity, as measured by increases in respiratory rates 
greater than three SD from the mean upon subsequent inhalation challenge. 
(Rapid shallow breathing is an early response to chemical stimulation of 
bronchial C-fibers (Coleridge et al., 1983)).  Significant pulmonary sensitivity was 
seen in 2 of 12 animals challenged with 5 ppb TDI vapor, in 4 of 12 animals 
challenged with TDI-protein conjugates, in 5 of 12 animals challenged with 
toluene monoisocyanate-protein conjugates, and in none of the animals 
challenged with the unconjugated protein carriers alone. 
Marek et al. (1995) investigated the induction of lung injury and development of 
airway hyperresponsiveness in rabbits with acute exposure to 5, 10 or 30 ppb 
TDI.  Eight rabbits per group were anesthetized and intubated for pulmonary 
function tests to increase the effective dose in the lower airways and the lung.  
Exposure to TDI four times each over a period of one hour did not significantly 
alter airway resistance, dynamic elastance, slope of the inspiratory pressure 
generation, arterial pressure or arterial blood gas tensions.  Airway 
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responsiveness to aerosols of 2% acetylcholine (ACh) was measured before and 
after each TDI exposure.  No effect by ACh was seen in rabbits exposed to 5 ppb 
TDI for up to 7 hrs.  With exposure to 10 ppb TDI, the amplitude of the ACh­
constrictor response, indicated by changes in dynamic elastance, had increased 
by almost 2-fold by the third hour of TDI exposure, with similar increases in 
airway resistance and the slope of the inspiratory pressure generation also 
recorded.  Exposure to 30 ppb TDI resulted in a steeper increase in these 
pulmonary responses following 2% ACh exposure.  The authors concluded that 
the increased airway resistance to ACh in the rabbits exposed to TDI is an early 
indication for the development of obstructive lung disease. 
Since TDI exposure may elicit both pulmonary and immune responses, it is of 
interest to compare the relative levels of exposure that elicit these respective 
responses.  Guinea pigs received whole body exposure to 0, 0.02, 0.2, 0.6, or 
1.0 ppm TDI as an aerosol comprising an 80:20 mixture of the 2,4- and 2,6­
isomers 3 hr/day for 5 days (Aoyama et al., 1994).  Three weeks following these 
induction exposures, all animals were challenged with a 15 min exposure to 0.02 
ppm TDI while in a body plethysmograph to measure respiration rates.  The 
pulmonary response was assessed as the percentage increase in respiratory 
rate.  Compared to controls, an increase of at least 3 standard deviations 
measured during and 60 minutes after the challenge exposure was considered 
significant.  By this criterion, animals induced by exposure to 0.2 ppm and above 
showed significant pulmonary responses.  There was, however, no linear 
correlation between the intensity of the pulmonary responses and the dose used 
for induction.  Whether this is related to the ability of TDI to act both as a sensory 
irritant, thereby decreasing respiratory rate, and as a pulmonary irritant that 
increases respiratory rate is not clear.  Alternatively, the breathing rate during 
induction was not reported and may have decreased, consistent with TDI’s 
sensory irritating properties. 
The breathing rate increase measured during the subsequent challenge by 
Aoyama et al. (1994) may reflect pulmonary changes associated with the 
immune response.  The number of animals responding at each dose level was 
also not different among exposure groups.  The time course of IgG production 
was followed and the first TDI-specific antibodies were detected in some of the 
animals 6 days following the first induction exposures to 0.2 ppm and above.  By 
13 days, all animals in these groups had demonstrable anti-TDI IgG.  In this 
study, 0.02 ppm represents a threshold above which both pulmonary and 
immune responses were observed.  Although these responses were not seen 
when the induction dose was 0.02 ppm, once the animals had been sensitized by 
higher induction doses, a challenge exposure to 0.02 ppm was sufficient to elicit 
pulmonary responses. 
In a protocol similar to Aoyama’s above, Karol (1983) exposed guinea pigs to 
0.02, 0.12, 0.36, 0.61, 0.93, 4.70, 7.60, or 10 ppm TDI and, beginning on day 22, 
examined animals for production of TDI-specific antibodies, and for dermal and 
pulmonary sensitivity to TDI.  TDI-specific antibodies were found with exposures 
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of 0.36 ppm and above with the antibody titers reflecting a dose-dependent 
increase through 0.93 ppm.  Respiration rates were observed to decrease in a 
dose-dependent fashion during the sensitizing exposure to TDI.  At exposures of 
0.61 ppm and above, respiratory rates were depressed at least 50% after one 
hour.  However, upon subsequent inhalation challenge with 1% TDI-guinea pig 
serum albumin conjugate, pulmonary responsiveness was measured as an 
increase in respiration rate.  Similar to the results for antibody production, 
pulmonary effects were only observed in animals sensitized with 0.36 ppm TDI 
and above.  The pulmonary effects correlated to the presence of antibodies, but 
not to their titer. 
Pauluhn (2014) developed a respiratory sensitization/elicitation protocol in Brown 
Norway rats to determine a threshold dose of TDI for elicitation of asthma-like 
responses in sensitized, re-challenged rats.  The focus of the study was to 
duplicate at least some phenotypes typical of diisocyanate-asthma using two 
cutaneous exposures to induce and boost systemic sensitization. Pauluhn and 
Poole (2011) found that skin-sensitization with MDI produced a more pronounced 
subsequent response upon inhalation challenge with MDI as compared to 
repeated inhalation-only sensitization, so a similar protocol was used for TDI. 
Pauluhn (2014) notes that both the priming response and the elicitation response 
are linked to irritation/inflammation of the susceptible lung airway tissue. Thus, 
the dose must be high enough to overcome the scrubbing ability of peptides and 
proteins in lung lining fluid of the upper airways and reach susceptible lung 
structures in the posterior airways.  As measured by changes in tidal volume that 
are a result of stimulation of the C-fiber-related alveolar Paintal reflex, this TDI 
dose was determined to be about 81 mg/m
3 or higher.  Neutrophilic granulocytes 
(PMNs) in BAL fluid were used as the endpoint for allergic pulmonary 
inflammation in the rats.  This was supplemented by physiological measurements 
characterizing nocturnal asthma-like responses and increased nitric oxide in 
exhaled breath. 
A C x t regimen in which concentration (C) was held constant and time (t) was 
variable yielded the best dose-response relationship for the dermally-sensitized 
rats as long as C was high enough to overcome the scrubbing capacity of the 
upper airways (Pauluhn, 2014). In rats that were primed with three previous 
exposures to 85 mg/m
3 TDI for 30 min each, the author identified a NOAEL of 
1000 mg TDI/m
3 x min for TDI-induced asthma in rats using his C x t (in which t = 
10, 30 or 60 min) escalation challenge protocol.  The author then calculated a 
human-equivalent 8-hour worker exposure of 3 ppb from the rat NOAEL, which 
included a dosimetric adjustment factor of 3 for conversion from obligate nose 
breathers (rats) to oronasal breathers (humans).  This breathing adjustment was 
based on findings in HDI from Shroeter et al. (2013). 
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6. Chronic Toxicity of Toluene 
Isocyanate exposure, including TDI exposure, is one of the leading causes of 
occupational asthma, characterized by bronchial inflammation with lymphocytic 
infiltration and eosinophilia, airway hyperresponsiveness, and airway remodeling 
(Chan-Yeung, 1990).  In clinical investigations carried out by Baur et al. (1994) 
detailed evaluation of case histories and clinical data of 621 isocyanate workers, 
247 of whom reported symptoms, showed that the predominant diagnosis was 
bronchial asthma followed by chronic bronchitis, rhinitis, conjunctivitis, and 
several other less common disorders including allergic alveolitis.  Another 
pulmonary endpoint investigated by many researchers is an accelerated decline 
in pulmonary function (such as decreased FEV1) with chronic TDI exposure in the 
absence of occupational asthma. 
6.1.  Chronic Toxicity to Adult Humans 
6.1.1.  Pulmonary Function as Measured by FEV1 
FEV1 is one of the most common pulmonary function tests examined in 
occupational studies.  It is helpful to review typical FEV1 loss in worker and 
general populations first before comparing pulmonary function decrements in 
diisocyanate worker populations.  In healthy adults, FEV1 has been found to 
decline at a rate of about 25 ml/yr (Anees et al., 2006).  In asthmatic subjects and 
smokers with chronic obstructive pulmonary disease, declines of about 40 ml/yr 
and 60 ml/yr, respectively, have been found.  Examined longitudinally, the Six 
Cities Study observed individual rates of FEV1 loss increased more rapidly with 
age in never-smoking adults (Ware et al., 1990).  Their longitudinal model gave 
rates of loss in males increasing from 16.9 ml/yr at age 25-29 to 58.0 ml/yr at age 
75-78.  In females, rates of loss increased from 14.6 ml/yr at age 25-29 to 41.7 
ml/yr at age 75-78. 
In a large steelworker population of 475 participants, smoking, being overweight, 
excess weight gain over time, and dust exposure at work were all related to a 
lower level (as measured cross-sectionally) and a steeper rate of decline of FEV1 
loss (as measured longitudinally) of pulmonary function (Wang et al., 1996).  In 
this worker group (age at midway 40 yrs), FEV1 loss examined longitudinally in 
current-, ex- and never-smokers was 53, 44, and 37 ml/yr, respectively.  In a 15­
year follow-up study of a general population, the unadjusted decline in FEV1 
among subjects with asthma was 38 ml/yr, as compared with 22 ml/yr in those 
without asthma (Lange et al., 1998). 
6.1.2.  Prevalence and Characteristics of Diisocyanate-Induced Asthma 
The prevalence of occupational asthma due to diisocyanates was estimated by 
Baur (1990) to be anywhere between 0 (seat production of a car manufacturer 
with no detectable TDI air concentration) and 30% (car equipment plant 
atmosphere with a permanent TDI concentration of 5-10 ppb).  In occupational 
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studies where TWA TDI concentrations were kept below 5 ppb, the prevalence of 
asthma was generally below 1% (Ott et al., 2003).  
Exposure to TDI or other diisocyanates in workers with diisocyanate-induced 
asthma may result in an immediate or delayed asthmatic symptom onset, or have 
a dual or recurrent character.  Diisocyanate challenges in diisocyanate-sensitized 
workers do not always correlate with nonspecific bronchial hyperactivity as 
evaluated by the methacholine challenge test.  For example, of 132 workers with 
an asthmatic response to methacholine 71% did not respond to diisocyanates, 
whereas 16% of those without methacholine hyperreactivity were positive in the 
diisocyanate challenge test (Baur et al., 1994).  Alternatively, Karol et al. (1994) 
found that airways hyperresponsiveness to methacholine in TDI-sensitized 
workers is a strong predictor of response to TDI provocation challenge, 
independent of atopy and serum IgE, and that serum IgE is associated with 
early-onset responses to TDI provocation challenge. 
Most studies find no evidence that atopy or smoking influences susceptibility to 
diisocyanate-induced asthma (Malo et al., 1992; Baur et al., 1994).  However, a 
case-referent study of TDI workers found smoking or history of either hay fever, 
eczema, or asthma increased the risk of developing TDI-related asthma 2-3-fold 
(Meredith et al., 2000). 
It has been proposed that brief episodes of high exposure are more likely to lead 
to diisocyanate asthma than long-term exposure to lower concentrations (Musk 
et al., 1988).  Thus, many researchers recorded average TDI concentrations as 
well as short-term peak exposures, most often defined as time spent at or above 
20 ppb.  However, it is still unclear what the relative importance of short-term 
high exposures and low, long-term exposures are in the development of 
diisocyanate-induced occupational asthma.  Some studies found a stronger 
association with continuous-type exposure leading to asthma compared to short-
term high exposures (Diem et al., 1982; Meredith et al., 2000). 
The persistence of pulmonary symptoms for months to years following cessation 
of diisocyanate exposure is not uncommon (Paggiaro et al., 1990; Paggiaro et 
al., 1993; Piirila et al., 2008).  Follow-up studies of patients with diisocyanate 
induced asthma resulting from TDI exposure typically find mild to moderate 
inflammatory responses, as indicated by elevated numbers of lymphocytes, 
eosinophils, and neutrophils in the bronchial submucosa and bronchial lavage 
fluid, along with epithelial damage and thickening of the basement membrane 
(Paggiaro et al., 1990).  In a long-term follow-up (11 years) study, asthma-like 
symptoms, bronchial hyperresponsiveness and airway obstruction improved, but 
did not normalize with cessation or reduction in TDI exposure (Talini et al., 2013). 
Improvement mainly occurred in subjects with an early diagnosis of occupational 
asthma and in patients with a lower baseline FEV1 no longer exposed to TDI. 
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6.1.3.  Latency Period for Onset of Isocyanate-Induced Symptoms 
In a study of 60 workers with isocyanate-induced asthma (predominantly to TDI), 
the average duration of exposure to isocyanates ranged between 8 and 15 years 
(Mapp et al., 1988).  The average duration of symptoms for these subjects before 
diagnosis was between two and five years showing that diagnosis was often 
delayed, but also that there can be a prolonged latent period between exposure 
and onset of respiratory symptoms.  In a more detailed study of the time of 
exposure before onset of occupational asthma, approximately 20% of 107 
subjects with isocyanate-induced asthma (principally HDI followed by MDI and 
TDI) had symptoms within the first year of exposure (Malo et al., 1992).  Nearly 
60% of subjects exposed became symptomatic after 5 years of exposure, with a 
mean latency period of 7.34 years between the start of exposure and the onset of 
symptoms. 
In a case-referent study by Meredith et al. (2000), symptoms began in 11 of 27 
workers (41%) in the first year of employment at a TDI plant, with nine occurring 
within 3 months.  The median duration employed at the time symptoms of 
asthma developed was 30 months.  The difference between cases and referents 
in mean 8-hr TWA exposure was most pronounced in these 11 matched sets (1.8 
ppb for the early-onset asthmatics and 1.3 ppb for asymptomatic referents 
performing similar jobs).  No difference in peak exposures between cases and 
referents was found.  Also, there seemed to be no association between current 
exposure to TDI and the development of asthma more than one year from first 
employment.  This finding suggested to the authors that the etiology of asthma 
due to diisocyanates which occurs soon after exposure may differ from asthma 
which develops after longer periods of employment. 
6.1.4.  Principal Occupational Studies 
Longitudinal studies are the primary means for assessing asthma onset 
prevalence and changes in pulmonary function with time in diisocyanate workers.  
The following longitudinal study summaries represent the most comprehensive 
studies that included both TDI exposure data and the subsequent pulmonary 
effects.  A few selected cross-sectional studies relevant for REL determination 
are also summarized. 
Diem et al., 1982; Weill et al., 1981 
The chronic REL is based on a prospective occupational study by Diem et al. 
(1982) of 277 male workers in a new TDI production plant.  This study has 
several strengths over other workplace investigations of TDI exposure, including 
minimal co-exposure to other irritating chemicals, extensive use of personal 
exposure monitoring devices, accounting of TDI-sensitized workers in the cohort, 
and in particular, detailed longitudinal analysis of workers from the start of 
exposure in a new TDI production facility. 
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Changes in pulmonary function, measured as changes in forced expiratory 
volume in 1 sec (FEV1), were assessed with nine examinations conducted over a 
five year period.  Baseline pulmonary function was established six months prior 
to the start of TDI production in 168 workers with no previously reported TDI 
exposure.  Personal 8-hr exposures were measured with continuous tape 
monitors (MCM Type 4000), but not until two years into the study.  A total of 
2,093 personal samples from 143 workers were collected.  The 8-hr TWA ranged 
from a minimum of 0.1 ppb to a maximum of 25 ppb, with a geometric mean of 
2.00 ppb and a geometric standard deviation of 2.94 ppb. 
Workers were divided into two groups.  The low exposure group comprised those 
exposed at or below 68.2 ppb-months (which is the cumulative exposure of a 
worker exposed to a geometric mean TDI level of 1.1 ppb for the entire 62 
months of the study), while the high exposure group comprised those above this 
level.  In the high exposure group, the 8-hr TWA concentration of TDI was above 
5 ppb for 15% of the time.  A further sub-grouping was based on smoking history 
(never, previous, current).  The arithmetic mean exposure level for the non­
smokers was 1.9 ppb TDI in the high-exposure group and 0.9 ppb TDI in the low-
exposure group (calculated by Hughes (1993) as cited by U.S. EPA (1995)).  The 
higher exposure group was further limited to those individuals who showed 
normal FEV1 levels (i.e. FEV1 to height ratio: FEV1/ht
3).  This was done since it 
has been observed that FEV1 level is inversely related to previous annual decline 
in FEV1.  Use of non-normal FEV1 levels could result in spurious associations 
between annual FEV1 decline and TDI.  Data were analyzed by the maximum 
likelihood weighted regression approach to account for inter-individual variability 
in the precision of the measurements (Diem and Liukkonen, 1988). 
Prevalence of bronchitis and dyspnea increased from pre-exposure baseline in 
the high exposure category, as measured by cumulative exposure, to a greater 
extent than in the low category.  However, these differences in symptom 
increases between low and high exposure categories were not statistically 
significant. 
Surveillance of the workers for onset of TDI sensitization was presented in Weill 
et al. (1981).  Of 277 workers in the study population, 12 men (4.3%) became 
clinically sensitized to TDI during the study.  Nine of these 12 men became 
sensitized after less than 12 months of TDI exposure; eight of those nine men 
were sensitized after less than four months of exposure.  The incidence of 
sensitization over the five years of the study was 0.9% per year.  Workers were 
identified as clinically “sensitive” if they developed recurrent respiratory signs and 
symptoms upon repeated exposure to low concentrations of TDI. 
In data provided by Weill et al. (1981), job positions held by the workers were 
stratified into three categories of TWA TDI exposure intensities of 6.8, 3.2 and 
1.6 ppb.  By this criterion 9 of 12 workers who became sensitized were in the 
high or moderate exposure groups.  Two other workers that became sensitized 
worked in low TDI exposure jobs.  The last sensitized worker was said to be 
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exposed to high TDI levels in laboratory work that was not measured during the 
study.  Six of the 12 workers had known major exposure in TDI spills, but the 
report did not specify which workers were exposed.  Workers in high and 
moderate exposure jobs were exposed to >5 ppb TDI for at least 24% of the 
time.  Workers in the low exposure jobs were exposed to >5 ppb TDI for only 3% 
of the time.  It was not stated specifically which exposure group the sensitized 
workers belonged to when stratified by two cumulative exposure groups (i.e., 
≤68.2 ppb-months group or >68.2 ppb-months group).  However, the authors 
reported that the sensitized workers likely did not affect the overall pulmonary 
function results. 
Linear regression analysis did not find a relationship between a decline in FEV1 
and TDI exposure when TDI exposure was treated as a continuous variable.  
Annual change in FEV1 was found to be significantly related to pack-yrs of 
smoking (p<0.01).  Table 3 presents the annual change in FEV1 dichotomized by 
three smoking categories and two cumulative exposure categories after adjusting 
for mean age (35.6 yrs) and FEV1 level.  The mean age used for FEV1 
adjustment was 35.6 yr and assumed a 5.8-ml increase in FEV1 annual decline 
per decade of age.  Among workers who never smoked, FEV1 was significantly 
reduced by 38 ml/year in the high-exposure group compared to the low-exposure 
group (p = 0.001).  However, among current and previous smokers, the decline in 
FEV1 was not statistically significant.  Comparing within the low exposure group, 
current smokers showed a mean FEV1 decline of 27 ml/year greater than never 
smokers (p = 0.004). 
Table 3. Annual Average FEV1 Change by Smoking and Cumulative 
Exposure
a 
Cigarette  Cumulative TDI Exposure  Annual 
FEV1 
decline 
p (one-tailed) 
Smoking  <68.2 ppb­
months 
>68.2 ppb­
months 
Never  1 ml/yr 
(n=35) 
-37 ml/yr 
(n=21) 
-38 ml/yr  0.001 
Previously  -12 ml/yr 
(n=31) 
-15 ml/yr 
(n=16) 
-3 ml/yr  ND
b 
Currently  -26 ml/yr 
(n=64) 
-37 ml/yr 
(n=35) 
-11 ml/yr  0.10 
aBased on 202 workers with FEV1/ht
3 ≥ 550 in Table 7 of Diem et al. (1982) 
bStatistical result was not presented but was not statistically significant (p>0.05) 
Similarly, in the low-exposure group, the mean annual decline in forced 
expiratory flow (25-75%) [FEF(25-75%)] was 81 ml/sec-yr greater among current 
smokers than among never-smokers (p = 0.003).  However, in the high exposure 
group, there was no effect of smoking history.  For never-smokers, the mean 
annual decline in FEF(25-75%) was 113 ml/sec-yr greater in the high exposure 
group than in the low-exposure group.  Thus the combined effects of smoking 
and TDI exposure were more pronounced in the low TDI exposure group. 
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The association between FEV1 annual change and time above 20 ppb 
dichotomized at 0.19 months was similar to that obtained using the cumulative 
exposure dichotomized at 68.2 ppb-months.  Among never-smokers, FEV1 was 
statistically significantly reduced (p=0.033) by 24 ml/year in the high-exposure 
group (>0.19 mo above 20 ppb) compared to the low-exposure group (≤0.19 mo 
above 20 ppb).  
This study suggests that an annual FEV1 and an FEF25-75 decline in excess of 
that due to aging occurred in the high exposure group.  A limitation of this study 
is that no unexposed reference group was included, although differences in FEV1 
were observed between low and high cumulative exposure groups. 
Peters and coworkers 
In one of the first studies to examine the longitudinal effects of TDI exposure on 
pulmonary function, Peters et al. (1968) published a series of reports following a 
group of polyurethane workers over three years.  In the first study, the pulmonary 
function of 38 workers was examined at the beginning and end of the work day 
(Monday).  Significant decrements in FVC (-190 ml, p<0.001) and FEV1 (-220 ml, 
p<0.001) occurred over the work day, with both nonsmokers and smokers 
showing similar responses.  Workers with respiratory symptoms of cough and 
phlegm showed greater decreases in FEV1 than workers without symptoms. 
Area exposures were determined at the time of the study by a colorimetric 
method called the Marcali method.  Individual exposure to TDI was not assessed. 
The limit of detection was said to be 0.1 ppb when air was sampled for 1 hour. 
Exposures ranged from 0.1 to 3.0 ppb, but had been 20-30 ppb in the 
polyurethane pouring area the previous year before ventilation was improved. 
Worker exposure duration ranged from 2 weeks to more than 10 years, with a 
mean of about 2 years. 
In a six month follow-up, 28 of the workers were again examined with the same 
pulmonary function tests (Peters et al., 1969).  The average FEV1 change for the 
group compared to six months earlier was -140 ml (annual average of -280 
ml/yr).  The limit of detection using the Marcali method was said to be 0.5 ppb 
with long sampling times.  At the time of the follow-up, the TDI concentration was 
9-12 ppb (n=2) in the pouring area and 4-5 ppb (n=2) near the stripping molds. 
The average FEV1 change for never-smokers (-160 ml/yr, n=11) was less than 
ever-smokers (-360 ml/yr, n=17), but not statistically significantly different.  The 
authors indicated larger sample sizes are needed to properly assess smoking 
differences.  No significant correlation was found between current smoking habits 
and any ventilatory function.  However, both lifetime packs and duration of 
smoking correlated significantly with one-day and six-month changes in FEV1. 
There was also a significant correlation coefficient (r=0.72) between one-day 
changes in FEV1 (measured six-months earlier) and six month changes in FEV1. 
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In addition, workers with respiratory symptoms (cough and/or phlegm) 
demonstrated greater falls in FEV1 than did asymptomatic workers.  Those 
workers with sputum in the morning and afternoon (n=8) had an annual average 
FEV1 change of -760 ml/yr.  The mean annual average FEV1 change for the 
other 17 workers was -100 ml/yr. 
One- and two-year follow up of the workers found a change in FEV1 of -120 ml at 
one year in the remaining 25 workers,  and a change of -220 ml (annual average 
of -110 ml/yr) at two years in 20 remaining workers (Peters, 1970).  Further 
information on TDI exposure and worker condition was not provided with the 
exception that the correlation for one-day changes in FEV1 (before and after 
Monday work) with one year changes was still strong (r=0.71).  The only data 
presented at the end of year three of the study showed that the decrement in 
FEV1 was still persistent in the workers (number unknown) at 120 ml/yr (Peters, 
1974). 
A more detailed report of the 18-month follow-up was conducted by Peters et al. 
(1970).  FEV1 was measured in the 19 remaining workers common to the first 
survey.  The cumulative change in FEV1 was -220 ml, or -147 ml/yr.  This change 
was statistically significant (p<0.02) and exceeded the expected change 
associated with aging and smoking.  It was unclear from the study how many of 
the remaining workers were asymptomatic for respiratory effects of TDI. 
Sampling using the Marcali method found TDI concentrations of 3.0 to 14.5 ppb 
in the pouring area (n=9 samples), and concentrations at or below the limit of 
detection (0.5 ppb) to 2.0 ppb in other areas of the facility (n=14 samples). 
Table 4 presents the overall summary of changes in FEV1 found in the workers 
over the three years of the study. 
Table 4. Mean change in FEV1 in polyurethane workers over three years of 
study by Peters and coworkers 
Follow-up period  Annual average 
change in FEV1 
(ml/yr) 
Number of 
workers 
p-value 
6 mo  -280  28  <0.02 
1 yr  -120  25  <0.02 
1.5 yr  -147  19  <0.02 
2 yr  -110  20  <0.01 
3 yr  -120  *  * 
* Data not presented 
This study is limited by use of area exposure sampling with a method (i.e., 
Marcali) that may seriously underestimate the true TDI exposure at polyurethane 
plants (Rando et al., 1984; Omae et al., 1992b).  This colorimetric technique 
measures only total TDI concentration, but the signal strength is different for the 
two TDI isomers.  The 2,6-TDI isomer gives about a 55% lower response than 
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2,4-TDI isomer.  In occupational settings, use of high performance liquid 
chromatography determined that 2,4-TDI is more efficiently reacted in the 
polymerization process.  Thus, a starting solution of 80% 2,4-TDI and 20% 2,6­
TDI has been shown to produce a contaminated air concentration dominated by 
the 2,6-TDI isomer during end stages of polyurethane production.  If the Marcali 
method was based on the signal given by the starting solution dominated by 2,4­
TDI, as was probably the case, the air concentration of TDI will likely be 
underestimated. 
Other limitations include lack of a control worker cohort, although the authors 
stated no FEV1 changes were found when the authors tested themselves (Peters 
et al., 1969).  The statistical analysis by the authors included workers 
experiencing respiratory symptoms.  However, Peters (1974) noted that although 
many of the workers experienced cough and phlegm, none experienced 
symptoms of chest tightness or shortness of breath from the TDI exposures. 
This finding would suggest that many of the workers had chronic bronchitis. 
Finally, no follow-up of the workers that left the study early was conducted. 
Wegman and coworkers 
In 1972 Wegman et al. (1974) examined 112 polyurethane workers exposed to 
TDI for acute pulmonary function changes during the work shift on the first day of 
the work week.  A follow-up of 57 remaining original workers was conducted two 
years later to investigate longitudinal pulmonary function changes (Wegman et 
al., 1977).  Comparison of the retested and lost workers did not find any selection 
bias.  Sampling included both area and personal sampling using the Marcali 
method, the sensitivity of which allowed the detection of TDI at 0.5 ppb.  A total 
of 118 personal and 14 area samples were taken to characterize 20 work 
stations over the course of the two-year study.  Ventilatory capacity was 
assessed on Monday morning following a three-day weekend. 
The average exposure values by job ranged from 0.5 to 9 ppb TDI.  To examine 
the results for a dose-effect relationship, three exposure categories were created, 
≤1.5 ppb, 2-3 ppb, and ≥3.5 ppb TDI.  Reports of symptoms collected on a 
standard questionnaire found the prevalence of cough and phlegm increased 
proportionally with increase in exposure. About 15% had responses consistent 
with chronic bronchitis (cough or phlegm for most days for three months of the 
year) but not associated with exposure.  Thirty percent reported wheezing 
occasionally or most of the time, and 10% reported dyspnea, but neither was 
associated with exposure.  OEHHA notes that these symptom findings suggest 
sensitization to TDI in some workers, but it was not investigated by the authors.  
Table 5 presents the annual average change in FEV1 over the two-year period of 
the study.  Analysis of Variance (ANOVA) showed a significant difference in loss 
of FEV1 according to exposure groupings (F = 5.2539, p<0.01).  The study 
authors report that possible confounding variables including age, months 
employed, smoking habits and lung size did not explain the differences. 
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Table 5. Two-year change in FEV1 1972-1974 and annual average change in 
FEV1 
Variable  Exposure Concentration (ppb) 
≤ 1.5 
(n=20) 
2-3 
(n=17) 
≥ 3.5 
(n=20) 
Months in plant  51.5  55.8  55.1 
# Nonsmokers  4  2  4 
2-yr ∆ FEV1 in ml, mean 
(±SD)
a 
-12 (204)  -85 (177)  -205 (185) 
FEV1 in ml/yr  -6  -43  -103 
a SD = standard deviation 
A follow-up examination was carried out on a Monday before work of the 
remaining workers (n=48) two years later in 1976 (Wegman et al., 1982).  Sixty-
nine personal and area samples were collected on the day of pulmonary function 
testing and employed the Marcali method as before to estimate TDI 
concentration.  Personnel records were used to estimate exposure to each 
worker during both the 1972-1974 and 1974-1976 time intervals.  Accurate 
information on exposure history and acceptable spirograms were obtained for 37 
of the 48 workers. 
Overall median TDI concentration for 1974-1976 was 3 ppb; the job identified as 
mixing and pouring has the highest median exposure of 7 ppb (range: 5 to 40 
ppb).  The population was divided into exposure categories of low (<2.0 ppb), 
medium (2.0-3.4 ppb), and high (>3.5 ppb) exposure. 
Upper and lower respiratory symptoms were found to be unrelated to exposure 
category.  The four-year change in FEV1 shown in Table 6 was statistically 
significantly related to exposure category by the ANOVA (p=0.007, F statistic not 
given), with the t-test showing a difference between the low and high exposure 
groups (p=0.002). 
Table 6. Four-year change in FEV1 1972-1976 and annual average change in 
FEV1. 
Variable  Exposure Concentration (ppb) 
≤ 2.0 
(n=13) 
2.0-3.4 
(n=13) 
≥ 3.5 
(n=11) 
Months in plant  82.5  81.1  67.0 
# Nonsmokers  4  2  3 
4-yr ∆ FEV1 in ml, mean (±SD) 
a  +2 (168)  -133 (184)  -242 (174)
b 
FEV1  (ml/yr)  ~0  -33  -60 
a SD = standard deviation 
b ANOVA f, p=0.007; t-test low vs. high, p=0.002 
Analysis of possible confounding variables including age, months employed, 
smoking habits and lung size did not explain the differences.  Comparison of the 
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survivor group with the initial cohort indicated that the restudied group was 
representative of the original group from 1972.  Thus no selection bias was 
introduced due to loss of subjects from the study. 
These studies are limited by use of the Marcali method that may have 
considerably underestimated the true TDI exposure.  OEHHA notes that the 
authors did not discuss the potential for TDI-sensitive workers being included in 
the analysis of longitudinal change in FEV1.  Also, sample size of the groups is 
small.  The authors state that smoking had no effect on FEV1, although this may 
have been a result of the small sample sizes. 
Musk and coworkers 
Analysis of FEV1 and respiratory symptoms was conducted in 259 workers at two 
polyurethane plants in 1971, with 107 available for follow-up examination five 
years later (Musk et al., 1982; Musk et al., 1985).  Over the five years of the 
study, 2,573 samples were collected by hand-held devices in breathing zone 
areas of subjects employed in the polyurethane pouring area.  Samples were 
also collected at other sites during the survey where highest exposures were 
encountered.  The sampling time was 20 to 60 min and analysis was done by the 
Marcali method.  Mean geometric TDI exposures over the last 4 years of the 
study were 1.5 ppb at Plant 1 and 1.0 ppb at Plant 2.  The 90
th percentile 
concentration was 5.0 ppb at Plant 1 and 3.6 ppb at Plant 2.  Very low 
concentrations of MDI were also present (0.6 to 0.3 ppb). 
No workers described acute exposure-related symptoms with exposure to TDI. 
Bronchitis was found to be more prevalent in smokers.  The mean annual decline 
in FEV1 for all subjects was 20 ml/yr, which was concluded by the authors to 
approximate normal aging declines.  For workers with no exposure to 
isocyanates (n=42), the annual average decline in FEV1 was 22 ml/yr.  The 
average annual decline in FEV1 for those exposed only to TDI (n=17) was 26 
ml/yr and not statistically significantly different from non-exposed workers.  In 
addition, no excess decline in FEV1 was reported for those workers exposed to 
MDI (n=25) or to both TDI and MDI (n=6).  Stepwise regression analysis showed 
the 5 yr decrement in FEV1 was significantly related only to current smoking. 
Workers that had been lost to follow-up had similar lung function to those who 
remained in the study. 
A ten-year follow-up was carried out in 42 remaining workers by Gee and Morgan 
(1985) in 1981.  A group of 12 additional workers at the plants with no isocyanate 
exposure was used as a control group.  The authors indicated the rate of decline 
of ventilatory capacity could not be accurately calculated since many of the 1971 
measurements were not valid.  This assertion had been refuted by Musk et al. 
(1985).  Nonetheless, Gee and Morgan (1985) did not detect an excess annual 
FEV1 decline in the exposed workers.  Follow-up of exposed workers that had left 
employment was not conducted, although the authors noted no worker 
compensation claims had been filed. 
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Omae, 1984 
Pulmonary effects were investigated in 106 workers at TDI production plants and 
39 referents in 1980, and in 64 workers and 21 referents on the 2-year follow-up 
in 1982 (Omae, 1984).  The workers wore personal MCM 4000 paper-tape 
monitors for TDI during working hours.  The numbers of samples collected from 
the followed workers were 161 in 1980 and 106 in 1982.  The mean duration of 
TDI exposure was 9.0 years in 1980 and 11.2 years in 1982. 
Arithmetic means of 8-hour TWA exposure concentrations were 0.7 ppb in 1980 
and 1.0 ppb in 1982.  Because the TDI process was automated, the workers 
spent much of their working time in clean areas.  The author indicated exposures 
occurred only during excursion into TDI areas.  As a result, only two of the TWA 
exposure concentrations exceeded 20 ppb.  Short-term concentrations 
(presumably 15 minutes) exceeding 20 ppb occurred in 15 of the 161 samples in 
1980 and 2 of 106 samples in 1982. 
No statistically significant differences were observed in the pulmonary function 
between the TDI workers and the referents, or in two-year reductions in FEV1 or 
FVC between TDI workers and the referents.  The change in FEV1 was -50 ml/yr 
among exposed and -65 ml/yr among the referents.  The change in FVC was -25 
ml/yr among exposed and -40 ml/yr among the referents.  Eight workers had 
exhibited episodes of acute asthmatic reactions soon after having begun their 
TDI jobs (mean exposure duration 11.7 yrs) but had continued working at the 
plants.  The authors imply these workers developed asthma prior to the start of 
the study in 1980 when TDI exposure was higher.  Specific TDI sensitivity was 
not assessed in these workers.  Although some of these individuals did show 
decreased pulmonary function (in particular, peak expiratory flow), the two-year 
decrement in pulmonary function in the asthmatic workers was not different from 
that in the other TDI workers. 
The author observed that the relatively low follow-up rate could introduce biases. 
Reasons for losses of about 80% of TDI workers were not related to TDI 
exposure.  However, follow-up of the remaining 20% of workers lost was not 
performed and appeared to fall into one of three categories: left due to plant 
closing, plant transfer, and absent from work on day of test.  Comparison of the 
data in 1980 between workers successfully followed and the 42 workers lost 
indicated negligible differences in pulmonary parameters and that selection 
biases were not considered a concern. 
Higher prevalence of sensory irritation was observed in the follow-up survey, but 
the symptoms were more often attributed to other chemical exposures.  Co-
exposure to other irritants included phosgene, chlorine, nitric acid and sulfuric 
acid, all of which are raw materials for TDI production. 
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Omae et al., 1992 
Fifty-seven polyurethane foam manufacturing workers and 24 reference workers 
were followed for four years to examine the long-term effect of TDI exposure on 
pulmonary function (Omae et al., 1992a; Omae et al., 1992b).  The workers wore 
personal paper-tape monitors for TDI (MCM 4000, MDA Sci.) on their chest 
during working hours.  The numbers of samples collected from the followed 
workers were 59 in 1981, 48 in 1983, and 52 in 1985.  The forced maximal 
expiratory flow-volume was examined in the same manner as in the first cross-
sectional study in 1981 and the follow-up surveys.  Adjustment for age and height 
of the forced expiratory flow-volume parameters was conducted using the 
prediction equations originally calculated by the authors with a group of non-
exposed males.  
None of these workers were considered hypersensitive to TDI.  The authors 
noted that the polyurethane workers had been engaged in their jobs for a mean 
of 13.3 years and sensitized workers may have left prior to the survey.  Thus, the 
workers examined may represent a survivor population.  Greater prevalence of 
eye irritation during or after work, nasal stuffiness or discharge in winter, and 
phlegm in the morning in winter were statistically significantly greater (p<0.05) in 
non- and ex-smoking polyurethane workers than in the non- and ex-smoking 
reference workers. 
Exposed workers were divided into two groups, workers in mold-type 
manufacturing processes (n=28) with low-level TDI exposure (TWA 0.1 ppb), and 
workers in mostly slab-type factories (n=29) where short-term exposure to TDI 
often exceeded 20 ppb.  The slab-type polyurethane workers were further divided 
into 2 subgroups, one subgroup consisted of workers (n=15) exposed to mean 
and maximal TWA concentrations of 8.2 and 30 ppb, respectively, and the other 
subgroup (n=14) was exposed to lower mean and maximal TWA concentrations 
of 1.7 and 4 ppb, respectively.  The ranges of peak exposure levels for the high 
and low slab-type PF workers were 30-80 ppb and 3-14 ppb, respectively. 
No differences were observed between the four exposure groups for average 
annual loss of FVC, MEF50 (forced expiratory flow at 50% FVC), and FEV1. 
However, greater than expected average annual loss in other flow-volume 
indices was observed (Table 7).  For the high exposed slab-type PF workers, 
greater than expected average annual losses (p<0.05) occurred for MMF 
(maximal mid-expiratory flow), FEV1% (FEV1/FVCx100), and MEF25 (forced 
expiratory flow at 25% FVC).  The average annual loss in these three indices 
was also greater in the high exposed slab-type workers compared to workers 
exposed in mold-type factories (p<0.05).  Finally, the high exposure slab-type 
workers also showed a greater average annual loss in PEF (peak expiratory flow) 
compared to the reference workers.  For the lower exposed slab-type PF 
workers, greater than expected average annual losses (p<0.05) occurred for 
MMF and MEF25. 
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Table 7. Statistically significant average annual loss indices among high-
exposed and low-exposed slab-type workers, mold-type workers and 
reference workers. 
Variable  Worker Exposure Group (mean ± SD) 
Slab workers 
High exposure 
(n=15) 
Slab workers 
Low exposure 
(n=14) 
Mold workers 
(n=28) 
Reference 
workers 
(n=24) 
TWA Exposure  8.2 ppb  1.7 ppb  0.1 ppb  0 ppb 
MMF  -2.39±4.13
a  1.91±3.02
b  0.11±2.96  -0.30±2.39 
FEV1 %  -0.89±0.96
a  0.19±0.63  -0.10±0.94  -0.29±0.88 
MEF25  -3.28±5.64
a  3.38±4.39
b  1.01±4.37  -0.50±5.49 
PEF  -0.38±1.46
c  0.66±1.79  0.61±1.61  0.72±1.66 
a p<0.05 against expected value of average annual loss and mold workers 
b p<0.05 against expected value of average annual loss 
c p<0.05 against reference workers 
The average annual loss of pulmonary function over 4 years was larger in 
smokers than in non-smokers, although the differences were not significant.  The 
lack of an effect due to smoking, the authors noted, was probably because the 
number of subjects was too small to detect significant differences.  The lack of 
differences in annual average loss between the low exposed slab-type workers 
compared to reference workers suggested to the authors that TWA 
concentrations of 1.7 ppb and a maximal TWA level of 4 ppb with short-term 
peaks up to 14 ppb may not cause long-term pulmonary function loss in those 
who are not hypersensitive to TDI.  However, the authors concluded that 
pulmonary function loss occurred in workers with short-term TDI exposures 
above 20 ppb (i.e., 30-80 ppb) and TWA exposure to 8.2 ppb. 
Co-exposure to other chemical irritants occurred in the workers during PF 
manufacturing processes.  Some of these chemicals include tertiary amines, 
organic tin compounds, polyols, silicon oil, dichloromethane, freons and flame-
resistant agents. 
Jones et al., 1992 
Exposure to TDI was studied for effects on respiratory health of workers in two 
plants manufacturing polyurethane foams (Jones et al., 1992).  TDI levels were 
measured at yearly intervals for 5 yr (1982 to 1986) at Plant 1 and for 4 yr (1982 
to 1985) at Plant 2.  Workplace concentrations were determined using the MCM 
TDI-sensitive paper-tape continuous monitoring system.  A total of 258 workers 
wore monitors on 507 shifts producing 4,845 measurements.  To improve 
accuracy in recording peak exposures and time-weighted averages under 
conditions of fluctuating TDI concentrations, a sample collection pattern of 12 min 
on, followed by 24 min of no sampling, was repeated during the 8-hr work shifts 
to produce up to 14 evenly spaced 12 min samples.  The lower detection limit 
was 1 ppb before 1983, and 0.5 ppb from 1983 on.  Samples showing no 
detectable TDI were assigned a value of one-half the lower detection limit (LDL). 
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With additional limited sampling done in the 1970s, personnel records were used 
to track each employee’s career, assigning exposures as the TDI level in ppb 
times the number of months worked in specific job groupings in the plants. 
Cumulative exposure, in units of ppb x month, is the sum of all such doses; 
average exposure is cumulative exposure divided by length of employment. 
There were 394 workers present at the start of the study, and, through the fourth 
examination, a total of 435 had worked in one or the other plant.  Six yearly 
spirometry examinations were performed on the workers to assess respiratory 
health and estimate rates of annual change in lung function. 
Of 4,845 personal TDI monitoring measurements, 50% reached or exceeded the 
LDL, 9% reached or exceeded 5 ppb, and 1% exceeded 20 ppb.  In a group of 
jobs involving exposure to foam ingredients or freshly produced foam, the 
respective figures were 68%≥LDL, 20%≥5 ppb, and 4%≥20 ppb.  Mean TDI 
concentrations by specific job category ranged from 4.47 ppb for foam production 
(plant 2) to 1.17 ppb for “other”. 
At initial interview of 380 workers, a trend for increased prevalence of “chronic 
bronchitis” (cough or phlegm for more than 3 months yearly in the previous 2 
years) with increasing cumulative exposure (hire to start of study) was observed, 
with prevalences in low, middle and high terciles of 2.6, 6.5, and 14.3%, 
respectively.  Terciles refer to any of the two points that divide an ordered 
distribution into three parts, each containing a third of the population.  The 
exposure terciles presumably refer to exposures of ≤32, >32 and ≤86, and >86 
ppb x month presented later in the paper.  Logistic regression analysis showed a 
significant association of prevalence with exposure (p<0.02) after controlling for 
smoking, age and sex.  Mean initial lung function (percent predicted) and mean 
decline in FEV1 were indicated as marginally worse in those with chronic 
bronchitis (data not shown).  At the time of follow-up examinations of the 
remaining workers (n=262), 12 workers had been identified as developing TDI-
sensitization, 6 of whom were tested and confirmed by TDI challenge. 
When initial pulmonary function values (hire to start) were presented by exposure 
tercile, the percent of predicted FEF25-75 in the highest tercile (>86 ppb x month) 
showed a statistically significant reduction (Table 8).  No differences were 
observed for FEV1 and FVC as a result of cumulative exposure to TDI. 
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Table 8. Initial pulmonary values by exposure tercile 
Variable  Tercile Exposure, Hire to Start (ppb x month) 
≤ 32 
(n=108-120) 
> 32, ≤ 86 
(n=109-121) 
> 86 
(n=112-121) 
Years in plant  4.45±0.50
a  6.34±0.28  17.56±0.55 
FEV1, % pred  107.4±1.1  106.3±1.2  104.2±1.4 
FVC, % pred  107.7±1.1  106.1±1.0  105.1±1.2 
FEF25-75, % pred  88.0±2.0  91.0±2.4  82.3±2.3
b 
FEV1/FVC, % pred  97.0±0.6  97.0±0.7  96.3±0.7 
a All values presented as mean±standard error 
b Difference among means: p<0.025 
Mean initial FEV1 and FVC in Table 8 were above 100% of predicted values. 
The reason cited by Jones et al. was the “healthy worker effect”, which often 
results in working populations derived from the general population that exceed 
the health of the general population as a whole. 
When cumulative TDI exposure was treated as a continuous variable (in 
increments of 100 ppb x month) there was a marginally significant effect 
(p<0.063) on FEF25-75 over all smoking categories.  Each increment of 100 ppb x 
month was associated with a reduction in FEF25-75 of 2.3% predicted.  When the 
effect of smoking on initial pulmonary function was examined, a significant 
reduction was found only in current smokers; for each 100 ppb x month 
increment, associated reductions of 4.3% of predicted FEV1 value (p<0.0003) 
and 4.4% of predicted FVC value (p<0.0001) were observed. 
Jones et al. also presented a longitudinal analysis of pulmonary function change 
for the workers over the five years of the study (Table 9).  The observed mean 
annual declines were steep in relation to expected values, but no statistically 
significant difference was observed. 
Table 9. Observed mean annual change in pulmonary function values in 
relation to expected values 
Cigarette  Lung Function (in relation to expected values) 
Smoking  FEV1  FVC  FEF25-75 
Never  -53 ml/yr  -51 ml/yr  -76 L/sec-yr 
Previously  -59 ml/yr  -59 ml/yr  -71 L/sec-yr 
Currently  -67 ml/yr  -66 ml/yr  -99 L/sec-yr 
When annual change was studied using weighted multiple regression followed by 
weighted stepwise multiple regression, the authors could find neither smoking 
nor measures of cumulative or average exposure were significantly related to 
annual change.  The FEV1 change was -6 ml/yr for current vs. never smoker 
(p<0.3).  Examining only the highest tercile (>86 ppb x month) of exposure, mean 
FEV1 annual changes were virtually identical across the smoking categories: -65, 
-61, and -61 ml/yr in current, ex-, and never-smokers, respectively. 
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The authors concluded that their study showed evidence of past and ongoing 
adverse effects on respiratory health, but was only attributable in part to 
measured and estimated TDI exposures.  Although the authors discussed their 
confidence in the reliability of their data, they could not fully rule out 
misclassification of exposure or co-exposure to other workplace chemicals as 
contributors to effects not fully explained by TDI exposures. 
Clark and coworkers 
This longitudinal study represents the largest investigation of the pulmonary 
effects of TDI-exposed workers at low concentrations (Clark et al., 1998).  A 
population of 780 polyurethane workers in 12 United Kingdom factories was 
followed for five years to determine whether longitudinal declines in ventilatory 
capacity and the occurrence of respiratory symptoms were related to TDI 
exposure.  The workers were divided into three subgroups: a “high” exposed 
worker group that manufactured the polyurethane products, a low-exposure 
handling group that handled cold polyurethane after manufacture, and a control 
group of factory office workers with minimal background exposure.  During the 
study, 88 workers left.  The average time in the study for the remaining 692 
workers was 4.3 yrs. 
Continuous tape monitors (MCM type 4000) were used throughout the study and 
were capable of measuring TDI concentrations between 1 and 40 ppb.  A total of 
2,294 measurements were collected.  The UK 8-hr (5.8 ppb) and 15-min (20 ppb) 
maximum exposure limits were exceeded in 4.7% and 19% of the samples taken, 
respectively.  The short-term exceedances were all from the high exposed group. 
In all, 8.8% of the observed peak measurements were at or above the level of 
detection of 40 ppb.  Although MCM monitors are used for short-term exposure 
estimates, these monitors have a minimum resolution time of 9-10 min for TDI.  
This duration may underestimate very short duration peaks.  A portable ion-
mobility spectrometer with a rapid response time (on the order of a few seconds) 
was used post-study to monitor the peak concentrations from some of the 
manufacturing processes.  Transient TDI peaks of up to 200 ppb were recorded, 
which equated to MCM-measured peaks of up to 30 ppb. 
The high-exposed group of 521 workers had an in-study mean daily cumulative 
exposure of 9.6 ppb-hr, and an 8-hr TWA exposure of 1.2 ppb.  In a summary of 
the industrial report by Garabrant and Levine (2000), the in-study mean daily 
cumulative exposure for the handler group and the office worker group was 5.0 
and 2.5 ppb-hr, respectively.  Based on an 8-hr workday these were said to be 
equivalent to average TWA daily exposures of 0.6 ppb for the handlers and 0.3 
ppb for the office workers.  Clark et al. noted that some HPLC samples taken in 
the control and handling areas showed TDI levels were below the level of 
detection (0.1 ppb) for this method.  Given some baseline “noise” on the MCMs, 
which has a higher detection limit (1 ppb), the assigned exposures for such 
subjects may have been overestimated. 
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Health questionnaire responses found a statistically significant increase in 
wheezing in the high-exposure group (p<0.01) and the low-exposure handling 
group (0.01<p<0.05).  Those workers who left the study from the high-exposed 
and low-exposed groups reported an increased incidence of breathlessness, 
wheeze and chest illness as compared with those not leaving.  This includes 7 of 
24 cases of respiratory sensitization identified during the study. 
The 24 cases of TDI-sensitization identified during the course of the study were 
presumably from the total of 780 workers examined.  Thus, 3.1% of workers 
became sensitized resulting in an annual incidence of 0.6% over 5 years.  The 
published study did not indicate which exposure group these workers were in, but 
the industrial report by Bugler et al. (1991) and summarized by Ott (2002) 
indicated that 14 of 18 new hires that became sensitized after the start of 
surveillance had jobs with routine short-term TDI exposures above 20 ppb. 
Three others that became sensitized had jobs with routine short-term exposures 
of 10-19 ppb.  The last of these 18 workers had a low exposure job, but had 
previous work in exposed areas with routine exposure >20 ppb.  The FEV1 
decline in sensitized workers shown in Table 10 was greater than those not 
sensitized, but was not found to be statistically significant (p=0.29). 
For the lung function measurements, linear regression analysis found no TDI-
exposure related effect on FEV1, FVC, peak flow and FEV1/FVC% for any of the 
exposure groups.  The mean annual decline in FEV1 was 38 ml/yr for the 
exposed group of 521 workers.  Mean annual declines in FEV1 for the handler 
and control groups were not presented by the authors.  A subgroup of male fitters 
and electricians in the exposed group with irregular TDI exposure, shown as 
maintenance workers in Table 10, did not have a different annual change in FEV1 
compared to the remaining male exposed group (p=0.25).  Female workers in the 
exposed group (n=49) were not included in this analysis. 
Linear regression analysis found a smoking-related effect on FEV1, which was 
not considered statistically significant by the researchers (0.05<p<0.1).  The 
smoking group represented a subset that smoked >15 cigarettes/day; their FEV1 
declined at a rate of 7 ml/yr more than that of nonsmokers (Table 10).  The 
authors noted there was a suggestion of an increased decline in FEV1 with 
increasing TDI exposure in non- and ex-smokers as compared with smokers, but 
was not found to be statistically significant. 
For the study population the average decline in FEV1 determined for the 88 
workers who left during the study (leavers) was not significantly different from 
that recorded for the other workers (non-leavers) (Table 10). 
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Table 10. Summary of FEV1 Annual Change Comparisons from Clark et al. 
(1998) 
Variable  FEV1 Annual 
Change 
High- exposure group 
Low-exposure (Handler) group 
“Control” group 
-38 ml/yr 
NS
a 
NS 
Nonsmoker
b (n=157) 
Smoker (n=253) 
-29 ml/yr 
-36 ml/yr 
TDI-sensitized (n=24) 
Not TDI-sensitized (n=756) 
-49 ml/yr 
-38 ml/yr 
Non-leavers (n=692) 
Leavers (n=88) 
-38 ml/yr 
-40 ml/yr 
Exposed group naïve workers (n=119) 
Exposed group non-naïve workers (n=402) 
-34.5 ml/yr 
-39.5 ml/yr 
Exposed maintenance male worker subgroup (n=95) 
Remaining exposed male workers (n=377) 
-34 ml/yr 
-41 ml/yr 
a NS: Not stated in the report 
b The n represents the population of nonsmokers.  It was unclear from the study if ex-
smokers were included in this group or analyzed separately. 
Clark et al. also examined a subgroup of workers who entered the study after the 
first longitudinal measurements were made and had no known prior TDI 
exposure (naïve workers).  The naïve worker population (n=157) showed a 
decline in FEV1 of 36 ml/yr and non-naïves (n=623) showed a decline in FEV1 of 
39 ml/yr.  The difference was not statistically significant.  Additionally, exposed 
naives in Table 9 did not show a significant excess decline in FEV1 as compared 
to exposed non-naives (p=0.56). 
Longitudinal regressions on the data from naïve workers show an in-study mean 
daily excess decline in FEV1 (p=0.016) and FVC (p=0.026) in the early years of 
employment.  The effect sometimes occurred immediately following the first 
exposure and is suggestive of an irritant response affecting those already 
suffering from non-specific bronchial hyperreactivity, rather than being suggestive 
of an allergic mechanism.  It was not clear in the study if all naives were included 
in the analysis, or if only those exposed to TDI during manufacturing processes 
were included.  Further analysis of naïve subjects for more than 4 years did not 
demonstrate an excess decline in pulmonary function as compared to non-
naives.  Thus, further deterioration did not occur in naïve workers, but neither 
was there recovery to pre-employment values that would indicate a “spirometry­
learning effect”.  
A follow-up was conducted over the period of 1997-1998 on 251 workers – the 
majority from the original population of 780 workers (Clark et al., 2003).  The 
authors called this a survivor population due to large attrition rates from factory 
closures and industry restructuring that occurred between studies.  The available 
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survey records from about 60% of all leavers indicated that respiratory illness 
was the reason for leaving in 2.3% of cases.  Any workers diagnosed with TDI 
sensitization had been removed from exposure and were no longer available in 
the current study.  As in the previous study, workers were divided into a high-
exposed (n=175), low-exposed (handling) (n=26) and low-exposure “control” 
(n=50) groups.  Personal measurements were recorded only for the exposed 
group.  Of the 1,004 measurements recorded as a mean cumulative exposure in 
ppb-hr, only 1.3% were in excess of 46.4 ppb-hr (equivalent to 5.8 ppb TDI over 
an 8 hr workshift),  This is a reduction from the 6.9% over the period 1981-1986 
observed in the previous study.  Mean exposure was 8.4 ppb-hr (equivalent to 
1.05 ppb TDI).  
Allowing for the effects of age, gender and smoking habits, regression analysis 
for the high-exposed group showed no relationship between the annual losses of 
FEV1 and FVC, and the mean daily exposure to TDI (Clark et al., 2003).  Annual 
declines for the high-exposed group with a mean age of 48 yrs at the end of the 
study were 35 ml per year for FEV1 and 30 ml per year for FVC.  These results 
are similar to what was reported previously in Clark et al. (1998).  The small 
handling group showed excess declines in both FEV1 and FVC (data not shown 
in study) compared to the control subjects.  The low n and the higher proportion 
of smokers in this group were attributed by the authors as causes for this effect. 
Their conclusion was that the study did not provide evidence of a TDI-related 
decline in FEV1 and FVC.  
Ott et al., 2000 
Ott et al., (2000) conducted an analysis of employees ever assigned (n=313) to a 
TDI production unit at a manufacturing complex for >3 months during the period 
1967 to 1992.  The workers were compared to a group of frequency matched 
referents (n=158) without known exposure to TDI.  The duration of TDI unit 
assignments averaged 5.7 and 4.7 years among men and women employees, 
respectively, with a range of 3 months to 30 years.  Reports during visits to the 
occupational clinic of incidents related to TDI and annual periodic examination 
results (questionnaire, physical findings, and spirometry) were abstracted and 
assessed relative to industrial hygiene estimates of exposure to TDI. 
Exposure estimates were initially conducted by area sampling in 1967 with a Uni­
jet TDI-in-air sampler.  Personal monitoring by the paper tape method (MCM4000 
personal monitor) began in 1976.  Starting in 1989, personal sampling for TDI 
was performed by OSHA method 42, which uses glass fiber filters coated with 1­
(2-pyridyl)piperazine followed by solvent desorption.  Analysis was by HPLC.  A 
job-exposure matrix approach was used to estimate individual exposure to TDI. 
Job specific work histories were coded for each person and linked to industrial 
hygiene measurements.  Peak exposure and TWA concentrations were 
aggregated on a job and time specific basis for three job groups with potentially 
low, medium, and high exposure to TDI.  Cumulative dose estimates (ppb­
months) were computed by multiplying the mean TWA concentration during a 
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particular job assignment by the time spent on that job (expressed in months) 
and summing across all job assignments. 
Regression analysis showed that TWA estimates declined significantly over time 
for all job groups.  Area sampling between 1967 and 1973 were mostly <10 ppb, 
with concentrations of 60 to 80 ppb in high exposure areas.  Personal 8-hour 
samples collected by the paper tape method from 1976 to 1988 averaged 5.9 
ppb TDI (n=156).  Eight hour samples collected by the filter method between 
1989 and 1997 averaged 2.8 ppb TDI (n=84).  The TWA estimates for high 
exposure jobs were 9.9 ppb TDI before 1985, and <5 ppb after 1985. The 
average TWA concentration after 1985 across all jobs and times was 4.2 ppb 
TDI.  Table 11 presents the distribution of the average concentration of TDI for 
the 313 workers over their entire work career.  
Table 11. Average TDI concentration across all jobs in the TDI unit, and the 
number (n) and percentage of workers (%) in each exposure group. 
Average TDI concentration 
(ppb) 
n  % 
<1.0  13  4.2 
1.0-2.9  113  36.1 
3.0-4.9  59  18.8 
5.0-6.9  94  30.0 
>7.0  34  10.9 
Incidents of exposure to TDI were reported by 77 different employees and 
included 58 incidents related to asthmatic or allergic skin reactions in 29 different 
workers (19 with asthmatic reactions only, nine with skin allergies only, and one 
person with both asthma and skin allergies).  The yearly incidence of asthma 
induced by TDI was 1.1%, but was higher before 1980 (1.8%) than after 1979 
(0.7%).  The incidence for workers assigned to the TDI unit for at least 20 years 
was estimated to be 11.5%. 
Spirometric data obtained before 1980 were judged to be unacceptable due to 
data quality.  The average number of lung function tests per employee was 7.5 
and the average interval between the earliest and most recent test was 9.3 
years.  Cross sectional analysis of FVC, FEV1 and FEV1/FVC% based on the 
most recent spirometry test found age, height, race, and sex were significant 
predictors of FVC and FEV1.  Pack years smoked was a significant risk factor for 
FVC, FEV1 and FEV1/FVC%. 
The TDI concentration and cumulative dose were not significant predictive 
factors in the full model or in models without occupational asthma as a covariate. 
An additional set of analyses carried out for 119 never-smokers also found no 
significant relation between outcome of spirometry and either TDI concentration 
or dose.  In addition, cross-sectional analysis was carried out with the earliest 
available lung function test to determine if previous exposure to TDI was 
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associated with lung function tests.  Neither TDI concentration nor cumulative 
dose was significantly related to these tests.  However, occurrence of previous 
incidents of exposure to phosgene, a chemical used in production of TDI, was 
associated with declines in both FEV1 and FVC. 
Longitudinal analyses were performed to estimate the annual change in FVC and 
FEV1 for various subgroups of the population with >3 lung function tests covering 
an interval of >2 years.  Declines in FVC and FEV1 were greater among cigarette 
smokers than never-smokers, but cumulative dose of TDI was not significantly 
related to the annual decline in either FVC or FEV1 (Table 12).  The authors 
concluded that in agreement with other studies conducted in workplaces with 
exposures ranging up to 5 ppb TWA and where active medical surveillance and 
exposure monitoring programs were in place, there was little evidence of a 
relation between exposure to TDI and either FVC or FEV1 decrement.  This 
study, however, relied on some retrospective construction of exposures using 
different measurement techniques; thus, exposure misclassification could be a 
problem. 
Table 12. Estimated annual change in FEV1 and FVC in selected subgroups 
Population Subgroup  Lung Function Value 
FEV1  FVC 
Men 
Exposed  (n=209) 
Referents  (n=65) 
Women 
Exposed  (n=10) 
Referents  (n=12) 
-37 ml/yr 
-35 ml/yr 
-20 ml/yr 
-14 ml/yr 
-37 ml/yr 
-34 ml/yr 
-27 ml/yr
a 
-14 ml/yr 
Men, never smokers 
Exposed  (n=67) 
Referents  (n=25) 
-31 ml/yr 
-36 ml/yr 
-33 ml/yr 
-34 ml/yr 
Men, ≥20 cigarette pack-yrs 
Exposed  (n=72) 
Referents  (n=24) 
-43 ml/yr 
-44 ml/yr 
-44 ml/yr 
-41 ml/yr 
a FVC statistically different (p=0.03) from controls but referent women had more pack-yrs 
smoking (14.8 vs. 4.6) and follow up interval nearly 5 yrs longer for referent women. 
Bodner et al., 2001 
In this longitudinal study at a Texas chemical manufacturing facility from 1971 
through 1997, 305 TDI manufacturing workers and 581 hydrocarbons workers 
never employed in isocyanate processes were examined to determine if TDI was 
associated with changes in respiratory measures (Bodner et al., 2001).  Accurate 
work history records and data from routine medical surveillance examinations 
were used to trace changes in lung function of the workers.  Workers who spent 
at least 3 consecutive months in TDI-related departments were selected. 
Personal sampling over the duration of the study included the MCM Model 4000 
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paper-tape method, followed by use of the colorimetric Marcali method, and 
beginning in 1989, use of continuous monitors employing the colorimetric paper-
tape based method.  From 448 8-hour TWA TDI samples and known work 
histories, average TDI exposures and cumulative exposure estimates in ppb­
months were determined for each work segment for each worker.  Mean 
employment in TDI departments was 3.8 ± 4.1 yrs (SD). 
Mean TDI exposures were 2.3 ppb (SD±1.0 ppb) for 8-hour TWA, and 96.9 ppb­
months (SD±110.6 ppb-months) when expressed as cumulative TDI exposure 
per month.  Maximum individual worker TDI exposure was 5.2 ppb for 8-hour 
TWA and 639 ppb-months.  Since 1980, mean 8-hour TWA TDI exposures were 
at or below 3 ppb for all job categories.  When exposure was expressed as 
cumulative TDI exposures of 1-12, 13-60, 61-120, and >120 ppb-month, no 
difference in FEV1 due to TDI exposure compared to control values was 
observed, and no trend in FEV1 decline with increasing cumulative TDI exposure 
was observed.  The average annual FEV1 decline for all workers was 30 ml/yr.  
The authors concluded that the decline in FEV1 was within normal limits of age-
related decline.  Significant declines in FEV1 were found among current smokers 
(1 ml/pack-yrs), those workers with asthma (114 ml/yr), and those with symptoms 
of shortness of breath (77 ml/yr). 
A drawback of this study was that no short-term estimates of high TDI exposures 
were examined by the authors.  Also, the health surveys used in this study could 
not adequately differentiate between occupational and nonoccupational asthma, 
although no workers were reportedly transferred due to TDI sensitization over the 
previous 10 years.  The prevalence of asthma, and clinical symptoms including 
persistent cough and shortness of breath were not different in TDI workers when 
compared to the control group.  Finally, pulmonary examinations of those that 
had left TDI operations had similar FEV1 values as those control workers that left 
the hydrocarbons departments (-32 ml/yr).  Thus, no negative impact on 
respiratory function was apparent after a worker had left the TDI operations. 
Table 13 presents a summary of the findings from the longitudinal studies 
presented here. 
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Table 13. Summary of Longitudinal Studies of TDI-exposed Workers 
Study  Industry type & 
Exposure 
Incidence of 
Sensitization 
Pulmonary Findings 
Weill et al.,  TDI manufacturing  12/277 (4.3%)  Mean FEV1 decline of 38 ml/yr 
1981; Diem  8-hr TWA: <1.1 (>5  0.9%/yr  greater in high vs. low dose 
et al., 1982  ppb 2% of time) & 
>1.1 ppb (>5 ppb 
15% of time) 
never-smokers 
No FEV1 annual loss when 
cumulative dose treated as a 
continuous variable 
Peters and  Polyurethane plant  None found,  Mean FEV1 loss 120 ml/yr after 1 
coworkers  Area sampling, 9­
12 ppb in pouring 
area, 4-5 ppb near 
stripping molds 
but workers 
that left  were 
not examined 
and 3 yrs exposure; greater in 
workers with respiratory 
symptoms (probably chronic 
bronchitis) 
Wegman  Polyurethane plant  ND*, but  Mean FEV1 loss after 4 yr 
and  Area and personal  sensitized  exposure: 
coworkers  sampling; ≤2.0, 2.0­
3.4, & ≥3.5 ppb 
groups 
workers likely 
included in 
analysis 
60 ml/yr in ≥ 3.5 ppb group 
33 ml/yr in 2.0-3.4 ppb group 
No change in ≤ 2.0 ppb group 
Musk et al.,  Polyurethane plant  No indication  Mean FEV1 loss after 5 yr 
1982  20-60 min sampling 
at peak exposure 
Mean 1.0-1.5 ppb 
(90
th %tile - 5 ppb) 
of sensitized 
workers 
exposure: 
26 ml/yr in TDI workers 
22 ml/yr in controls 
FEV1 loss significantly related 
only to smoking 
Omae, 1984  TDI manufacturing 
Personal 
monitoring 
8-hr TWA 0.7-1.0 
ppb 
8/106 (7.5%) 
sensitization 
probably prior 
to study 
Mean FEV1 loss after 2 yr 
exposure: 
50 ml/yr in TDI workers 
65 ml/yr in controls 
Omae et al.,  Polyurethane plant  ND, may have  No average annual change in 
1992  8-hr TWA personal 
monitoring: 
0.1, 1.7 and 8.2 
ppb and control 
groups 
only examined 
“survivor” 
population 
FEV1 over 4 yrs for all groups. 
Lower MMF, MEF25, and FEV% 
in high vs. low exposure 
(p<0.05); lower PEF in high vs. 
control (p<0.05) 
Jones et al.,  Polyurethane plant  12/262 (4.6%)  Marginal effect on FEF25-75 
1992  8-hr TWA: 1.2 to 
4.5 ppb depending 
on job 
Overall: 
9% of samples 
>5 ppb 
In polyurethane 
production jobs: 
20% of samples 
≥5 ppb 
0.9%/yr  (p<0.063) when cumulative TDI 
exposure treated as a 
continuous variable. 
Ave annual FEV1 loss over 5 yrs: 
53 ml/yr in never smokers 
59 ml/yr in previous smokers 
67 ml/yr in current smokers 
Declines steep in relation to 
expected values but not related 
to exposure 
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Study  Industry type & 
Exposure 
Incidence of 
Sensitization 
Pulmonary Findings 
Clark et al.,  Polyurethane  24/780 (3.1%)  Ave. annual FEV1 loss over 5 
1998  plants 
8-hr TWA: 
0.3 ppb control 
group 
0.6 ppb low group 
1.2 ppb high group 
4.7% of samples 
exceeded 5.8 ppb 
0.6%/yr 
At least 14 
sensitized 
were from the 
high exposure 
group 
yrs: 
38 ml/yr in high exposed group; 
not different from control or low 
exposed groups 
Mean daily excess decline in 
FEV1 (p=0.016) in early 
exposure years of naïve workers 
Clark et al.,  Follow-up of Clark  ND; only  No relationship between the 
2003  et al., 1998 
1.05 ppb for high 
group: 
1.3% of samples 
exceeded 5.8 ppb 
No exposure data 
for other two 
groups 
examined 
survivor 
population 
annual losses of FEV1 and FVC, 
and the mean daily exposure to 
TDI in high exposure group. 
Excess declines in FEV1 and 
FVC (data not shown in study) 
compared to the control subjects 
Ott et al.,  TDI manufacturing  20/313 (6.4%)  Mean exposure duration 9.3 yrs 
2000  Ave 8-hr TWA 
1976-88: 5.9 ppb 
1989-97: 2.8 ppb 
(1.1%/yr) 
incidence 
1.1%/yr before 
1980; 
incidence 
0.7%/yr after 
1979 
Ave annual FEV1 loss over: 
37 ml/yr all workers 
35 ml/yr controls 
31 ml/yr never smoker workers 
36 ml/yr never smoker controls 
Annual FEV1 loss not associated 
with exposure 
Bodner et  TDI manufacturing  ND  No difference in FEV1 among 
al., 2001  305 TDI workers: 
8-hr TWA 2.3 ppb 
(96.9 ppb-month) 
3.8 yrs mean 
employment 
581 control workers 
cumulative exposure groups of 
1-12,13-60, 61-120 and >120 
ppb-mo 
No FEV1 change compared to 
controls 
No trend in FEV1 decline with 
increasing cumulative TDI 
exposure 
* ND – Not determined 
6.1.5.  Additional supporting studies 
Surprisingly few of the longitudinal studies summarized above gave strong 
evidence of a quantitative exposure-response relationship for TDI-induced 
asthma.  The following case-referent and cross-sectional studies provide the best 
available data for exposure levels to TDI that can result in development of 
occupational asthma.  A few studies also provide evidence for decreased lung 
function in non-sensitized workers with long-term exposure. 
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Lee and Phoon, 1992 
This cross-sectional occupational study presents evidence of pulmonary function 
decrements with prolonged high occupational exposures to TDI (Lee and Phoon, 
1992).  Pulmonary effects of TDI exposure were studied in 26 mixers from eight 
east Asian factories making polyurethane foam, and in 26 unexposed controls 
matched for age, race and smoking.  Mean exposure duration for the TDI 
workers was 6.6 yrs.  Personal breathing zone samples (n=24) were collected 
only during the foaming process when TDI exposure was the highest, a duration 
of 30 to 92 minutes.  Analysis was by the Marcali method, so only mean 
exposure time could be determined and the exposure may be underestimated. 
The foaming process was carried out for 4 to 6 hours every day at 6 factories and 
for only about 4 hours per week at two factories that had automated the process. 
The mean TDI exposure concentration during the mixing process was 160 ppb 
(range: 10 to 500 ppb).  Prevalence of symptoms included increased eye 
irritation and cough in the mixers compared to unexposed controls.  Only one 
case of clinically overt wheezing was observed in exposed workers, and this 
subject was negative when tested by bronchial challenge to TDI.  The authors 
characterized the group of mixers as a survivor population in which only those 
workers that did not develop TDI-related asthma remained in the job. 
No statistically significant differences were observed in FEV1 or FVC between the 
TDI workers and the control group.  FEV1 of mixers was 3.4 L, and that of the 
controls was 3.5 L.  There was a statistically significant reduction (p=0.01) in the 
average ratio of FEV1/FVC and in diurnal variation of peak expiratory flow (PEF) 
rate (p=0.02).  Six mixers exhibited a diurnal variation in PEF of more than 15% 
on at least one day compared with none among the controls (p=0.01; Fisher’s 
exact test). 
Mixers with exposure of 10 years or more (n=7) had a significantly reduced FEV1 
(2.7 L; p<0.001) compared to those with less than 10 years of exposure 
(FEV1=3.5 L, n=19) and controls (FEV1=3.5 L, n=26).  FEV1 was reduced 16.4% 
in this group compared to predicted values.  Workers with >10 years of exposure 
were older (39.0 yrs) than workers with <10 years of exposure (28.8 yrs) and the 
controls (32.2 yrs), but FEV1 had been adjusted for age, height, race, and 
cigarette-yrs.  The mixers with >10 years of exposure also exhibited a reduced 
FVC (p<0.05 compared to mixers with <10 yrs of exposure only), FEV1/FVC 
(p<0.005 compared to control group only), and diurnal variation in PEF (p<0.05 
compared to controls only).  The authors suggested that the longer TDI 
exposures were associated with chronic airways obstruction. 
Huang et al., 1991 
This cross-sectional study from China compared the pulmonary function of 15 
painters (7 men and 8 women) exposed to high levels of TDI from polyurethane 
varnish with 18 referents with no history of TDI exposure (Huang et al., 1991).  
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The painters had a mean exposure duration of 7.5 yrs to TDI.  Referents (9 men 
and 9 women) were matched with regard to age, height, weight and smoking 
habits.  Area sampling with analysis by a colorimetric method on the day of 
pulmonary testing revealed TDI concentrations of 70-170 ppb during the 8-hr 
workshift. 
Respiratory symptoms included eye, nose and throat irritation in all exposed 
painters. Seven painters with chronic bronchitis, and four with longer exposure 
durations (9.5-17 yrs) reported dyspnea and wheezing during work.  Five 
painters had a positive response with patch testing to 0.1%TDI in petrolatum.  All 
symptoms were statistically significantly different compared to referents (p<0.01).  
Pulmonary function testing revealed reduced FEV1 in the painters compared to 
referents (2.04 L vs. 2.94 L, p< 0.05).  The %FEV1 and maximum mid-expiratory 
flow were also statistically significantly reduced in the exposed workers.  The four 
painters exhibiting wheeze and dyspnea during work, reported by the authors to 
be consistent with work-related asthma, had a much greater rate of decline than 
the other painters (data not shown).  
Meredith et al., 2000 
The quantitative relationship between exposure to diisocyanates and 
occupational asthma was investigated at several polyurethane plants (Meredith 
et al., 2000).  Workers with diisocyanate-induced asthma (n=27; 24 exposed to 
TDI and 3 exposed to MDI) were compared with referents (n=51) that were 
defined as workers without asthma, of the same sex as the case, who were 
working in the same area, both at the time the case started the job in which he 
developed asthma and when the diagnosis of occupational asthma was made. 
Exposures by job category were reconstructed based on records of personal 
paper-tape monitors. 
No difference was found between the 27 cases and 51 matched referents in 
estimated peak exposure (means 21.5 ppb and 22.5 ppb respectively), defined 
as the highest 15-20 min TWA exposure.  Mean 8-hr TWA exposure for cases 
(1.5 ppb) was slightly higher than for referents (1.2 ppb).  The odds of 
occupational asthma for those for whom estimated exposure to TDI was greater 
than the median concentration for the control group (1.125 ppb) were 3.2 times 
the odds for those exposed to lower concentrations (95% confidence interval 
0.96 to 10.6; p=0.06).  The odds of occupational asthma increased by 8% for 
each 0.1 ppb increase in 8-hr TWA exposure (p=0.06).  Overall, higher 
exposures seemed to be associated with increased risk of disease, but this was 
limited to those cases which occurred in the first year of employment.  A history 
of either hay fever, eczema, or asthma at the time of employment tripled the risk 
of developing occupational asthma (p=0.04), but no single factor was associated 
with significantly increased risk. 
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This study suggests that keeping 8-hr TWA exposure below 1 ppb significantly 
lowers the risk of TDI-induced asthma in a worker population.  A limitation of this 
study was that person-specific exposure measurements were not available, and 
so exposure was estimated from job title and date.  Referents were closely 
matched to cases and selected from the same work areas in an attempt to 
ensure a similar level of surveillance and a similar chance that occupational 
asthma would be diagnosed if it occurred.  This was done, the authors noted, to 
minimize the risk of selection bias, a common problem in case-control studies. 
Tarlo et al., 1997 
In this study conducted in Ontario, Canada, the ambient levels of isocyanates 
were compared between 20 plants with and 203 plants without cases of 
compensated isocyanate occupational asthma over a 4-year period from 1984­
1988 (Tarlo et al., 1997).  Sampling methods included Marcali and Nitro reagent 
methods.  Exposure was based on the highest level identified at a plant as a 
result of state-mandated monitoring at plants to ensure worker exposure does 
not exceed 5 ppb.  There were a total of 49 occupational asthma claimants in 
which exposure was attributed primarily or exclusively to TDI.  Some claimants 
also had potential exposure to MDI and/or HDI.  The overall estimated incidence 
of occupational asthma in the total 223 companies surveyed was 0.9% in the 4 
years of the study (56 out of 6,308 workers). 
A greater proportion of companies which had claims for occupational asthma was 
found in the higher exposure category (≥5 ppb) than in the lower exposure 
category (<5 ppb).  For TDI, the proportion was 30% (high) vs. 13.7% (low); the 
odds ratio (OR) was 2.7 (95% confidence interval (CI) of 0.7-10.6).  When 
combined across all isocyanate types, claims were significantly more likely to be 
from companies in the higher exposure category; 10 of 20 companies (50%) with 
claims were in the high exposure category vs. 50 of 203 companies (25%) 
without claims, OR: 3.1 (95% CI: 1.1-8.5, two-tailed p=0.03). 
6.2.  Chronic Toxicity to Infants and Children 
No studies of inhalation exposures to TDI among children were located. 
However, early life exposure to TDI may occur through inhalation and dermal 
contact with polyurethane products.  Although detectable levels of free TDI 
emitted from bedding materials have not been found, Krone et al. (2003) applied 
semiquantitative tests (i.e., wipe test) for isocyanate to polyurethane products, 
including mattresses, mattress pads, sofa padding, carpet pads and pillows, and 
detected free isocyanate in these consumer products.  When this bedding is 
used by infants, there is a potential for exposure of the developing immune 
system to TDI.  In fact, among children with 12 or more wheezing attacks in the 
previous 12 months, independent associations have been reported between 
severe wheeze and the use of  non-feather bedding, especially foam pillows 
(odds ratio 2.78; 95% C.I. 1.89 to 4.17) (Strachan and Carey, 1995).  It has also 
been observed that there is a higher incidence of asthma among first children 
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compared with their siblings (Karmaus and Botezan, 2002).  This is consistent 
with the use of new polyurethane products (bedding, car seats, etc.) by the first 
child while siblings often use hand-me-downs whose isocyanate content has 
diminished over time. 
These early life diisocyanate exposures may be significant since at birth, humans 
exhibit a dominant humoral, TH2, responsiveness (i.e., an atopic state).  During 
the first few years of life, the TH2 response converts to a more cellular (TH1) 
immune response characteristic of the mature adult immune system.  A delay in 
the transition from the predominant TH2 pattern to the more balanced TH1/ TH2 
response allows an atopic TH2 type response to persist longer, thus extending 
the period of vulnerability to environmental stressors and allergens, and 
increasing the likelihood of subsequent disease expression including asthma 
(Prescott et al., 1999). 
In animal models of TDI-induced asthma, TH2 cytokines were found to be 
decisive in the initial phase of asthma, in the priming of TH2 cells, and in the 
permeation of eosinophils into the airway lumen (Matheson et al., 2005b).  In 
other mouse models of asthma, a TH2-dominated sensitization was best 
achieved via dermal exposure followed by tracheal exposure, while exposure 
exclusively by inhalation prompted more of a TH1 type response (Ban et al., 
2006).  Thus if a TH2 response predominates, whether by previous activation or 
due to an early developmental stage, subsequent respiratory exposure may 
result in a substantial pulmonary inflammatory response.  Other examples of 
chemical stressors that can shift the immune response to a TH2 pattern are diesel 
exhaust and environmental tobacco smoke, both of which are strongly 
associated with asthma. 
6.3.  Chronic Toxicity to Experimental Animals 
One lifetime TDI exposure study in rodents has been carried out and reported by 
Loeser (1983).  Groups of male and female rats and mice (~40 rats and 30 mice 
per sex per level) were exposed to 0.05 and 0.15 ppm TDI by whole-body 
inhalation for 6 hr/day, 5 days/week for approximately 2 years.  In rats, 
termination of the study occurred at week 110 for males and week 108 for 
females.  TDI exposure did not affect mortality, although mortality was high in all 
groups (64 to 75%).  Male and female rats in the 0.15 ppm group gained less 
weight, but only during the first 12 weeks of exposure.  No treatment-related 
changes in haematological, blood biochemical or urinary parameters were seen. 
Organ weights were not affected by TDI exposure and no macroscopic changes 
were observed in the upper respiratory tract. 
Histopathology of the rat nasal turbinates in the Loeser report were reported 
separately by Owen (1984).  Seven rats per sex per level were examined at 6-, 
12- and 18-month interval sacrifices, respectively.  There were 26 to 37 rats per 
sex per level sacrificed and examined at termination of the study at 
approximately 2 years.  At 6-, 12- and 18-month sacrifice, nasal passages 
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showed a dose-related increased incidence of rhinitis mainly in the anterior 
portion of the nasal cavity (Table 14).  The lesions at 6-, 12- and 18-months 
showed similar incidences and severity grades regardless of exposure duration, 
so the data were combined in Table 14.  Rhinitis was generally characterized by 
squamous metaplasia/hyperplasia of the respiratory mucosa, with or without 
exudates in the lumen, and leukocyte infiltration.  In males, there was some 
degree of rhinitis in about half of the controls.  Female control rats were free of 
rhinitis.  
Table 14. Summary of Incidence of Grade Scores in the Anterior 
Respiratory Portion of the Nasal Cavity of Rats Exposed to TDI: Six-, 12­
and 18-Month Sacrifice Combined 
Histopathology  TDI Exposure Group (ppm) 
Score
a  Male 
0 
Male 
0.05 
Male 
0.15 
Female 
0 
Female 
0.05 
Female 
0.15 
# examined 
Grade 0 
1 
2 
3 
4 
21 
13 
3 
4 
1 
0 
20 
12 
2 
4 
2 
0 
21 
2 
0 
5 
11 
3 
21 
21 
0 
0 
0 
0 
21 
12 
4 
5 
0 
0 
20 
7 
6 
5 
2 
0 
% with grade 3-4  5  10  67  0  0  10 
a Histopathological grading scores: (0) unremarkable, (1) minimal - rhinitis present in 
<25% of mucosa, (2) slight – rhinitis present in 25-50% of mucosa, (3) moderate – 
rhinitis present in 50-75% of mucosa, and (4) marked – rhinitis present in >75% of 
mucosa. 
At 2-year sacrifice, the dose-related increased incidence of rhinitis was still 
apparent, although some female control rats now showed some degree of 
rhinitis.  In particular, the incidence and severity grade of the lesion had 
increased in exposed females at two years more than in exposed females in the 
earlier sacrifice groups (Table 15).  To a lesser extent, nasal lesions were also 
found in the middle and posterior nasal cavity.  Overall, Owen (1984) concluded 
that the nasal lesions were a low grade injury considered to be evidence of local 
irritation.  The lesion was not accompanied by any unusual proliferative changes 
suggestive of any oncogenic effect. 
Appendix D1  47  Toluene Diisocyanate          
     
       
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
             
             
             
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
                   
                         
                   
 
       
     
       
           
     
     
     
    
     
   
 
    
 
 
       
       
 
       
   
       
       
   
 
        
   
Public Review Review  July 2014 
Table 15. Summary of Incidence of Grade Scores in the Anterior 
Respiratory Portion of the Nasal Cavity of Rats Exposed to TDI: 2-Year 
Sacrifice 
Histopathology  TDI Exposure Group (ppm) 
Score
a  Male 
0 
Male 
0.05 
Male 
0.15 
Female 
0 
Female 
0.05 
Female 
0.15 
# examined 
Grade 0 
1 
2 
3 
4 
37 
17 
8 
9 
3 
0 
35 
18 
5 
11 
1 
0 
30 
4 
5 
8 
12 
1 
35 
25 
7 
3 
0 
0 
26 
15 
4 
4 
3 
0 
36 
10 
10 
13 
3 
0 
% with grade 3-4  8  3  43  0  12  44 
a Histopathological grading scores: (0) unremarkable, (1) minimal - rhinitis present in 
<25% of mucosa, (2) slight – rhinitis present in 25-50% of mucosa, (3) moderate – 
rhinitis present in 50-75% of mucosa, and (4) marked – rhinitis present in >75% of 
mucosa. 
In mice, Loeser (1983) observed a statistically significant increase in mortality in 
females of both dose groups, although not strictly dose-related (60% in controls, 
77% low-dose, 74% high-dose).  The female mice in the 0.15 ppm group showed 
a high incidence of death within a 3 week period during the 10
th month.  Rhinitis 
in this group was considered to be associated with exposure and was 
predominantly seen in the animals dying during the study.  Statistically significant 
reduced weight gain was observed in the high dose group for both males and 
females.  No treatment-related changes in hematological, blood biochemical or 
urinary parameters were seen.  The major pathological change observed in both 
groups was a dose-related increased incidence and severity of either chronic or 
necrotic rhinitis (epithelial atrophy, mucous and squamous metaplasia, 
inflammation, focal destructive rhinitis with debris).  Lesions of variable incidence 
and severity were also seen in the lower respiratory tract (interstitial pneumonitis, 
catarrhal bronchitis) and in the eyes (keratitis) of some mice, with a higher 
incidence in the 0.15 ppm group.  Pathology tables for the mice, including 
specific incidence and severity grades for respiratory tract findings, were not 
provided in the report. 
As a result of the numerous human occupational studies that exist in the 
literature, animal studies conducted in the ppm range of TDI are less relevant for 
derivation of the chronic REL and are not summarized here.  The principal 
chronic exposure studies (i.e., <2 year exposure) that conducted toxicity studies 
at TDI concentrations in the range of occupational exposures are summarized. 
Animal models for TDI-induced allergic rhinitis and asthma have been developed 
and suggest a duration-dependent nature.  Female C57BL/6 mice were given a 
subchronic nose-only exposure to TDI vapors (80:20 2,4:2,6 isomers) at 20 ppb 
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4 hr/day, 5 d/wk for 6 weeks, or a single acute, 2 hr exposure to 500 ppb 
(Matheson et al., 2005b).  These exposures were followed 14 days later with an 
acute 1 hr challenge exposure to 20 ppb.  In this model, 6 weeks is the period 
during which sensitization to TDI develops.  Three control groups included air­
exposed/air-challenged, TDI-exposed/air-challenged, and air-exposed/TDI­
challenged mice.  A portion of each group was sacrificed 24 hr after the 
challenge for the collection of blood and bronchioalveolar lavage fluid (BALF). 
Another portion was sacrificed 48 hrs after challenge for airway and pulmonary 
histopathology.  The exposure period resulted in different immunological 
response patterns.  Following the challenge exposure, total IgE levels were 
elevated 10-fold over controls (p < 0.05) in mice with the subchronic exposure 
but not significantly different from controls in acutely exposed mice.  However, 
both subchronic and acute exposures significantly raised TDI-specific IgG 
antibodies (p < 0.05) compared to non-detectable levels in controls. 
Subchronically exposed mice exhibited histopathological changes in the nares 
and lungs consistent with an inflammatory response including significant 
infiltration by neutrophils, lymphocytes, eosinophils, and macrophages. 
In acutely exposed mice, Matheson et al. (2005b) observed that inflammatory 
cells were only slightly elevated relative to controls.  Consistent with this, 
inflammatory cytokines (IL-4, IL-5, IFNγ and TNFα) were significantly (p < 0.05) 
elevated following subchronic but not acute exposure.  However, both exposure 
regimens resulted in significant degenerative cellular changes including loss of 
cilia, goblet cell metaplasia, septal exudates, hyaline droplet formation and 
epithelial hyperplasia.  In addition, airway hyperreactivity, assessed by 
methacholine challenge, was significantly elevated in animals sensitized to TDI 
and challenged with TDI regardless of exposure duration.  These results suggest 
that long term, low level TDI exposure caused a marked allergic response 
including airway inflammation, eosinophilia, goblet cell metaplasia, elevated IgE 
and TDI-specific IgG, and TH1/ TH2 cytokine expression, all characteristic of 
allergic asthma.  Acute exposure however, did not present evidence of either TH2 
or eosinophil involvement, and the observed cellular changes likely were 
predominantly a result of upper airway irritation rather than an immune response. 
To examine the effects of long-term, low-level exposure on bronchial hyper-
responsiveness, animals were exposed to 0.02 ppm TDI 6 hr/day for 70 days 
resulting in a total exposure of 8.67 ppm x hr (Karol, 1983).  This was 
comparable to the total exposure of 9.2 ppm x hr received by animals breathing 
0.61 ppm for 3 hr/day for 5 days.  Whereas animals receiving the higher level 
(0.61 ppm), short term exposure displayed bronchial hyper-responsiveness and 
antibody production, none of the animals with low level (0.02 ppm) TDI exposure 
developed antibodies or pulmonary responsiveness upon challenge.  These 
results suggest that in the absence of a sensitizing event, chronic low level TDI 
exposure may not elicit either pulmonary hyper-responsiveness or immune 
responses.  However, as observed in the occupational study by Diem et al. 
(1982), pulmonary effects (decreased FEV1) were associated with a low TDI 
concentration of 1.9 ppb. 
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Pulmonary function was investigated in guinea pigs exposed to 0 or 20 ppb TDI, 
6 hr/day, 4 days/wk for 14 weeks (Wong et al., 1985).  Each week during 
exposure, eight animals were randomly selected and placed in a whole-body 
plethysmograph to record respiratory frequency, pressure change (which is 
proportional to tidal volume) and the ventilatory response to 10% CO2.  These 
animals were compared to guinea pigs receiving 1.4 ppm TDI 3 hr/day for 4 
days, a concentration expected to cause pulmonary damage.  Exposure to 20 
ppb TDI had no effect on baseline pressure change, respiratory frequency or the 
ventilator response to CO2, whereas exposure to 1.4 ppm TDI increased baseline 
pressure change and respiratory frequency, but diminished the CO2-induced 
increase in pressure change.  All animals exposed to 1.4 ppm showed multifocal 
subchronic interstitial inflammation at terminal sacrifice, whereas only 2 of 24 
animals exposed to 20 ppb TDI showed patchy interstitial inflammation. 
Bronchial provocation challenge was also examined by Wong et al. (1985) with 
TDI antigens on days 37-38.  Four of 8 guinea pigs exposed to 1.4 ppm TDI 
exhibited pulmonary hypersensitivity.  No sensitivity was apparent in animals 
exposed to 20 ppb TDI or control animals. 
Immunologic and respiratory responses have been produced in dogs with airway 
challenge to TDI (Patterson et al., 1983).  In this model three anesthetized dogs 
received 1 mg/kg aerosolized TDI via tracheal tube every 2 weeks for 4 months, 
and then every 4 weeks thereafter for 6 months.  A dose of 1 mg/kg TDI every 4 
weeks was said to approximate 4 week exposure of a human at heavy work 
exposed to 20 ppb TDI.  After the biweekly exposures, the dogs developed 
systemic immune responses to TDI-dog serum albumin, which included IgG, IgA 
and IgM antibody responses and development of lymphocyte reactivity. 
Immediate-type airway responses occurred after the fourth TDI aerosolization, 
some of which qualitatively simulated IgE-mediated antigen-induced airway 
responses. 
6.4.  Toxicogenomics 
Even though diisocyanates are one of the most common causes of occupational 
asthma, only 5 to15% of exposed workers develop the disease.  Thus, genetic 
variability has been implicated in the susceptibility to occupational asthma by TDI 
and other diisocyanates.  A number of gene variants have been reported to be 
associated with increased sensitivity to the disease in workers (Table 16), which 
suggests that diisocyanate-induced asthma represents a complex disease 
phenotype determined by multiple genes.  Examples of genes include, but are 
not limited to, genes involved in immune regulation, inflammatory regulation, and 
antioxidant defense (Choi et al., 2009; Yucesoy and Johnson, 2011; Yucesoy et 
al., 2012).  The goal of genetic association studies is to provide more accurate 
information on interindividual variability, thereby contributing to better protection 
of sensitive human populations and to the establishment of more accurate 
exposure limits in the workplace. 
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A case-control study was conducted by Yucesoy et al. (2012) to investigate 
whether genetic variants of antioxidant defense genes are associated with 
increased susceptibility to diisocyanate-induced asthma (DA).  The study 
population consisted of 353 Caucasian French-Canadians in three groups: 95 
workers with specific inhalation challenge confirmed DA; 116 symptomatic 
diisocyanate workers with a negative specific inhalation challenge; and 142 
asymptomatic exposed workers.  Antioxidant defense gene variations for 
superoxide dismutase, glutathione-S-transferase and epoxide hydrolase and 
their interactions were found to contribute to DA susceptibility (Table 16). 
In a study population of 109 cases of workers with DA and 73 exposed non-
symptomatic controls, polymorphisms in glutathione-S-transferase genes were 
examined to look for associations with DA (Piirila et al., 2001).  Lack of the 
GSTM1 gene (null) was found to be associated with increased risk of DA.  In a 
later study on the same worker group, Wikman et al. (2002) investigated the 
possible role of N-acetyltransferase (NAT) genotypes in the development of DA. 
Positive associations for increased DA were found with slow acetylator 
genotypes and genotype combinations with a glutathione-S-transferase (GSTM1 
null) genotype. 
The human leucocyte antigen (HLA) class II molecules are also thought to be 
involved in the development of the immune response to diisocyanates.  HLA 
class II molecules are encoded by genes located within the major 
histocompatibility complex and present antigens from outside of the cell to T-
lymphocytes. These particular antigens stimulate the multiplication of T-helper 
cells, which in turn stimulate antibody-producing B-cells to produce antibodies to 
that specific antigen.  Mapp et al. (2000) examined the distribution of markers 
(DQA, DQB and DRB) for HLA class II genes in European Caucasians (67 TDI-
exposed workers with DA, 27 asymptomatic worker controls, and 101 normals).  
The frequencies of DQA1*0104 and DQB1*0503 were significantly increased in 
asthmatic subjects.  DQB1*0503 was also more frequent among asthmatic 
subjects compared with normal subjects. 
Kim et al. (2006) evaluated a Korean population for associations of HLA class I 
and II alleles with TDI-induced asthma.  Statistical significance was not found 
with single allele analysis.  However, two and three locus haplotype analysis 
showed several significant alleles as potential susceptible markers.  The authors 
identified the HLA haplotype DRB1*15-DPB1*05 as the most useful marker for 
predicting development of TDI-induced occupational asthma (OA) in the Korean 
population. 
A more recent study by the same Korean research group expanded on the earlier 
study by looking for associations of HLA class I and II alleles with TDI-induced 
asthma using high resolution analysis (Choi et al., 2009).  The Korean study 
population included 84 worker with DA, 47 asymptomatic controls and 127 
unexposed normal controls.  No significant association was found between allele 
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frequencies and TDI-induced OA.  However, two- and three-locus haplotype 
frequencies were found that were associated with TDI-induced OA compared to 
both asymptomatic workers and unexposed controls (DRB1*1501-DQB1*0602­
DPB1*0501, DRB1*1501- DQB1*0602, and DRB1*1501- DPB1*0501). 
CTNNA3 (alpha-T catenin) is a key protein of the adherence junctional complex 
in epithelial cells and plays an important role in cellular adherence.  The function 
of CTNNA3 in TDI-induced asthma is not known, but it has been shown that 
decreased expression of CTNNA3 may lead to increased susceptibility to TDI 
effects and contribute to development of DA (Bernstein et al., 2013).  A 
Caucasian study population including 132 workers with DA, 131 symptomatic 
workers with a negative challenge for DA, and 147 asymptomatic workers were 
examined to determine if genetic variants of CTNNA3 genes are associated with 
increased susceptibility to DA.  CTNNA3 minor allele homozygotes of rs7088181 
and rs10762058 SNPs were at increased risk for DA compared to the 
asymptomatic control workers, but not symptomatic workers with a negative 
challenge.  These same SNP CTNNA3 polymorphisms were also significantly 
associated with TDI-induced asthma in a group of 84 Korean workers with DA 
compared to 263 normal controls (Kim et al., 2009). 
Sixty-two workers with DA and 75 diisocyanate workers negative for DA were 
analyzed for SNPs associated with the immune response genes IL4RA, IL-13, 
and CD14 (Bernstein et al., 2006).  The TH2 cytokines IL-4 and IL-13 play key 
roles in B-cell IgE isotype class switching and are believed to at least partially 
determine expression of airway inflammation and allergic disease.  No 
associations were found with individual SNPs and DA when all diisocyanate 
workers (TDI-, MDI- and HDI-exposed) were considered.  When only HDI-
exposed workers were considered (34 with DA, 62 negative for DA), associations 
with immune response genes and DA were found.  The strongest associations 
were for the two-genotype variation combination IL4RA (150V) II and CD14 
(C159T) CT, and the three-genotype variation combination IL4RA (150V) II, IL13 
(R110Q) RR, and CD14 (C159T) CT. 
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Table 16. Variability in Observed Odds Ratio (OR) or p Value for Significant 
Genotype Variation Associations and Increased Susceptibility for 
Diisocyanate-Induced Asthma 
Reference  Ratio or p value  Genetic associations for DA 
OR=2.70
a 
(95%CI 1.38-5.27) 
p=0.004 
SOD2 (rs4880) superoxide dismutase single-
nucleotide polymorphism (SNP) Ala→Val 
substitution on SOD2 gene that decreases the 
activity of SOD2 
OR=6.10
a 
(95%CI 1.31-28.4) 
p=0.021 
GSTP1 (rs762803) glutathione-S-transferase 
SNP of unknown functional consequence 
Yucesoy et 
al., 2012 
OR=7.34
a 
(95%CI 2.04-26.5) 
p=0.002 
GSTM1*EPHX1 (rs2854450) copresence of 
glutathione-S-transferase (GSTM1) deletion and 
minor allele for epoxide hydrolase (EPHX1 
rs2854450) 
OR=8.55
a 
(95%CI 1.05-69.9) 
p=0.045 
EPHX1 (rs2740168)*EPHX1 (rs1051741) 
copresence of two EPHXs, rs2740168 variant 
and a variation (rs1051741) that reduces enzyme 
activity 
OR=10.36
b 
(95%CI 1.47-72.96) 
p=0.019 
EPHX1 (rs1051741) epoxide hydrolase minor 
allele 
OR=6.22
b 
(95%CI 1.95-19.82) 
p=0.002 
EPHX1 (rs2740171) epoxide hydrolase SNP 
minor allele 
Piirila et al., 
2001 
OR=1.89 
(95%CI 1.00-3.52) 
(no p given) 
GSTM1 (null) gene lacks enzyme activity (59 
cases and 29 controls with TDI, MDI or HDI 
exposure) 
Wikman et al., 
OR=7.77 
(95%CI 1.18-51.6) 
(no p given) 
NAT1 gene polymorphism for slow acetylation. 
TDI-exposed only (23 cases, 8 controls) 
2002  OR=4.53 
(95%CI 1.76-11.6) 
p=0.040 
GSTM1 (null)*NAT1 copresence (43 cases and 
20 controls with TDI, MDI or HDI exposure) 
P=0.005  HLA DQA1*0104 - 16 of 67 cases (23.9%), 0 of 
27 asymptomatics (0%) 
Mapp et al., 
2000  P=0.009  HLA DQB1*0503 – 14 of 67 cases (20.9%), 0 of 
27 asymptomatics (0%) 
P=0.027  HLA DQB1*0503 - 14 of 67 cases (20.9%), 9 of 
101 normals (8.9%) 
Kim et al., 
2006 
P=0.001 (cases vs. 
asymptomatics) 
P=0.003 (cases vs. 
normals) 
HLA DRB1*15-DPB1*05  - 10.6% in cases 
(n=110), 0% in asymptomatic controls (n=94), 
and 2.5% in normals (n=190). 
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Reference  Ratio or p value  Genetic associations for DA 
TDI-OA vs. AEC
a 
OR=4.43 
(95%CI 1.50-13.10) 
p=0.007 
DRB1*1501-DQB1*0602-DPB1*0501 – 16 of 84 
cases (19%), 1 of 47 asymptomatic workers 
(2.1%), and 4 of 127 normals (4%). 
Choi et al., 
2009 
TDI-OA vs. AEC 
OR=2.024 
(95%CI 1.14-3.59) 
p=0.016 
DRB1*1501- DQB1*0602 – 23 of 84 cases 
(27.4%), 6 of 47 asymptomatic workers (12.8%), 
and 15 of 127 normals (11.8%). 
TDI-OA vs. AEC 
OR=3.127 
(95%CI 1.38-7.08) 
p=0.006 
DRB1*1501- DPB1*0501 - 17 of 84 cases 
(20.2%), 2 of 47 asymptomatic workers (4.3%), 
and 4 of 127 normals (3.1%). 
Bernstein et 
OR=9.05 
(95%CI 1.69-48.54) 
p=0.01 
CTNNA3 (rs7088181) – SNP minor allele 
homozygote (130 cases, 147 asymptotic control 
workers) 
al., 2013  OR=6.82 
(95%CI 1.82-14.88) 
p=0.002 
CTNNA3 (rs10762058) – SNP minor allele 
homozygote (130 cases, 147 asymptotic control 
workers) 
Bernstein et 
OR=5.2 
(95%CI 1.65-28.24) 
p=0.008 
IL4RA (150V) II and CD14 (C159T) CT HDI 
workers with DA 39% vs 11% among DA-
negative workers 
al., 2006  OR=6.4 
(95%CI 1.57-26.12) 
p=0.01 
IL4RA (150V) II, IL13 (R110Q) RR, and CD14 
(C159T) CT HDI workers with DA 24% vs 5% 
among DA-negative workers 
a AEC: asymptomatic TDI-exposed control workers 
7. Developmental and Reproductive Toxicity 
To examine the developmental toxicity of exposure to TDI vapors, Tyl et al. 
(1999a) exposed mated female Sprague Dawley rats to 0, 0.02, 0.10, or 0.50 
ppm (25 per dose) of an 80:20 mixture of 2,4- and 2,6-TDI for 6 hr/day on 
gestation days 6-15.  Animals were terminated on gestational day 21 and 
examined for signs of fetal and maternal toxicity.  At 0.50 ppm, signs of maternal 
toxicity included reduced feed consumption and reduced weight gain, audible 
breathing and, among some animals, red nasal discharge.  Reduced weight gain 
was also observed at the lower doses but this was reportedly transient in nature. 
No maternal treatment-related lesions were observed at necropsy. In terms of 
developmental toxicity, there were no apparent treatment-related effects on the 
total number of corpora lutea, implants per litter, or percent live fetuses.  Of 111 
skeletal variations observed, the only treatment-related sign of fetal toxicity was 
poor ossification of cervical centrum 5 at 0.50 ppm.  The reported LOAEL for 
maternal and fetal effects was thus 0.50 ppm, with a corresponding NOAEL of 
0.10 ppm. 
The potential reproductive effects of TDI exposure were investigated in a two-
generation study, also by Tyl et al. (1999b).  Sprague-Dawley rats (28/sex/group) 
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were exposed beginning at 42 days of age to TDI vapors (80:20 mix of 2,4- and 
2,6-TDI) for 6 hr/day, 5 days/wk for 10 weeks at 0, 0.02, 0.08, or 0.3 ppm.  This 
was the parental or F0 generation.  During the 3-week mating period, gestation 
and lactation, exposures were increased to 7 days/wk.  F0 maternal rats were not 
exposed from gestational day 20 through postnatal day 4, but exposures 
resumed on postnatal day 5.  Randomly selected weanlings (F1) were exposed 
as described above for 12 weeks prior to mating, during the 3-week mating 
period, and throughout gestation and lactation.  Males of the F1 generation were 
terminated after delivery of the F2 generation; F1 females were terminated upon 
weaning of the F2 generation. 
Among F0 parents, reproductive parameters were unaffected by TDI treatment. 
In the production of the F1 generation, no treatment-related effects were seen on 
gestation length, litter sizes, sex ratios, pup body weights or weight gain.  In the 
F2 generation, a transient significant decrease in pup body weight gain was 
observed at the 0.08 and 0.30 ppm level.  At these exposure levels, pup body 
weight/litter was also depressed (transiently in females, permanently in males).  
In the F0 and F1, but not F2 generations, rhinitis showed a dose-dependent 
incidence and severity.  This study found no effects of TDI exposure on 
reproductive parameters in either the F1 or F2 generations. 
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8. Derivation of Reference Exposure Levels 
8.1.  Toluene Diisocyanate Acute Reference Exposure Level 
Study  Baur et al., 1994; Vogelmeier et al.,
 
1991
 
Study population  15 asthmatic and 10 healthy volunteers 

with no previous contact with
 
diisocyanates
 
Exposure method  Exposure chamber
 
Continuity
 
Asthmatic subjects  1 hr at 10 ppb (71 µg/m
3), 45 min break, 

then 1 hr at 20 ppb (142 µg/m
3)
 
Healthy subjects  2 hr at 20 ppb
 
Critical effects  ≥100% increase in Raw in asthmatics
 
LOAEL  71 µg/m
3 (10 ppb)
 
NOAEL  Not determined
 
Time-adjusted exposure  71 µg/m
3
 
LOAEL uncertainty factor  10 (for severe effect)
 
Interspecies uncertainty factor
 
Toxicokinetic (UFa-k)  1
 
Toxicodynamic (UFa-d)  1
 
Intraspecies uncertainty factor
 
Toxicokinetic (UFh-k)  1
 
Toxicodynamic (UFh-d)  √10 (protect children with asthma)
 
Cumulative uncertainty factor  30
 
Reference Exposure Level  2 µg/m
3 (0.3 ppb)
 
Acute Reference Exposure Levels (RELs) are levels at which infrequent one-
hour exposures are not expected to result in adverse health effects.  Sensory 
irritation and altered lung function of sensitive individuals are the main responses 
seen with acute exposure to TDI. 
The key study presented by both Baur et al. (1994) and Vogelmeier et al. (1991) 
was among the few controlled human exposure studies in which the total dose 
level of TDI was sufficient to elicit sensory irritation in normal and asthmatic 
subjects, and an asthmatic reaction in non-sensitized asthmatic subjects.  A 
supporting study by Fruhmann et al. (1987) observed similar results in asthmatic 
subjects using a similar exposure protocol. 
Pulmonary function in healthy subjects was not impaired with 2 hr exposure to 20 
ppb TDI, although 3 subjects reported sensory irritation.  In asthmatics, 1/15 
experienced a severe pulmonary response to 10 ppb during 1 hr of exposure, 
and 1/13 remaining asthmatics experienced a severe response to 20 ppb TDI 
after a 45 min break.  Five of 15 asthmatics reported pulmonary symptoms of 
chest tightness, rhinitis, cough, dyspnea, throat irritation, and/or headache during 
exposure.  The concentration at which these symptoms occurred was not 
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specified in the report.  The LOAEL from this study is 10 ppb (71 µg/m
3) for a 1 
hour exposure (with no NOAEL observed).  Only one of 15 asthmatics exhibited 
severe symptoms (100% increase in Raw) at 10 ppb.  However, symptoms of 
respiratory irritation may have occurred as low as 10 ppb (or slightly higher at 20 
ppb) in several other asthmatic subjects. 
A LOAEL-to-NOAEL uncertainty factor (UF) of 10 is applied for a severe effect 
(onset of asthma symptoms) occurring at the LOAEL.  Specific exposure 
durations to onset of symptoms were not presented by the authors. 
Concentration × duration studies in TDI-sensitized subjects observed that 
bronchial responsiveness was neither exclusively concentration- nor duration-
dependent (Vandenplas et al., 1993a).  Rather, the product of the two factors, 
i.e., total dose, was the main determinant.  This could explain why shorter 
duration exposure studies (15-30 min) with similar TDI concentrations did not 
elicit effects in asthmatics and non-asthmatics, although all the subjects in these 
studies were non-sensitized individuals.  No time adjustment was applied since 
the TDI response appears to be, at least in part, a concentration-dependent 
effect that is already addressed by the LOAEL-to-NOAEL uncertainty factor. 
A default toxicokinetic UF=1 was applied to the NOAEL based on the key human 
study that examined a sensitive subpopulation (i.e., asthmatic subjects).   It is 
not anticipated that there would be significant interindividual variability in 
toxicokinetics for TDI, which acts at the portal of entry.  TDI primarily affects the 
tracheobronchial region of the respiratory system.  Comprehensive data are 
available to show that children have lower tracheobronchial regional gas doses 
compared to adults (OEHHA, 2008).  The tracheobronchial minute volume (MV) 
to surface area (SA) is equal to 1 for adults, while children age 0 to 2 years has a 
MV/SA ratio of 0.5.  For older children age 2 to 15 years, the MV/SA ratio is 
roughly 0.8.  The toxicogenomics data for diisocyanates show gene variants 
associated with increased sensitivity up to10-fold greater in workers developing 
diisocyanate-induced asthma.  However, these findings address long-term 
exposures resulting in diisocyanate-induced asthma and is applied to the 8-hour 
and chronic REL derivations below.  An intraspecies toxicodynamic default UF of 
√10 was used to address any potential increased sensitivity of children with 
asthma compared to adults with asthma.  The total UF of 100, when divided by 
the POD of 10 ppb, generates an acute REL of 0.1 ppb (0.7 µg/m
3). 
Evidence of cross-reactivity of diisocyanates suggests that a first exposure to TDI 
could result in diisocyanate-induced asthma in an individual previously exposed 
and sensitized to a different diisocyanate.  As discussed above in Krone and 
associates, it is conceivable that infants could be sensitized with dermal 
exposure to diisocyanate-containing polyurethane products.  Subsequent 
exposure to low level airborne TDI could then result in asthmatic symptoms. 
However, definitive evidence that dermal sensitization resulted from exposure to 
these consumer products is lacking.  Exposure to TDI at concentrations as low 
as 1 ppb (7 µg/m
3) have resulted in an asthmatic reaction in sensitized 
individuals.  However, a study by Suojalehto et al. (2011) showed an asthmatic 
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reaction occurred in a sensitized individual exposed to MDI at a much lower 
concentration of 0.05 ppb (0.51 µg/m
3).  This finding suggests that once primary 
sensitization occurs it is probably not possible to identify a no effect level to 
protect all individuals that acquired specific hypersensitivity to diisocyanates. 
The same conclusion was presented in an International Consensus Report on 
Isocyanates (ICRI, 2002).  Thus, the acute REL for TDI is based on prevention of 
primary sensitization, but should in many cases be protective for previously 
sensitized individuals. 
In view of the concern for sensitization by exposures to TDI (which is discussed 
further in the derivation of the 8-hour and chronic RELs), it is appropriate to also 
consider whether repeated acute exposures at the acute REL level could cause 
sensitization.  Although acute RELs are defined for infrequent single exposures, 
it is possible that an acute increase in the exposure concentration might be 
repeated on an occasional basis, and this type of exposure pattern may promote 
sensitization.  However, in the study upon which the chronic REL is based, 0.9 
ppb was the NOAEL for five years of occupational exposure.  There is a 3-fold 
difference between this level for a regularly repeated exposure over five years 
and the acute REL of 0.3 ppb meant for infrequent exposures.  Therefore 
infrequent exposures at the level of the acute REL should be adequately 
protective for most individuals, although the possibility of a pulmonary response 
in certain hypersensitive individuals cannot be completely excluded. 
8.2.  Toluene 8-hour Reference Exposure Level 
The 8-hour Reference Exposure Level is a concentration at or below which 
adverse noncancer health effects would not be anticipated for repeated 8-hour 
exposures. 
The critical study and the time adjustment for the 8-hour REL is the same as that 
for the chronic REL below, resulting in the same health value for both 8-hour and 
chronic RELs.  For many substances, higher exposure levels are tolerable if the 
exposures are intermittent versus chronic, thus 8-hr RELs are typically higher 
than chronic RELs.  For TDI, the exposure level of the chronic REL was also 
chosen for the 8-hour REL as a more health-protective approach due to its 
sensitization potential, an effect that may occur with only intermittent low-level 
exposures.  Sensitization to TDI that occurs following an acute, high-level 
exposure primarily represents a neurological sensitization with only non-specific 
involvement of the immune system.  The development of TDI-specific IgE (and 
possibly IgG) antibodies requires longer-term exposures and may occur at low 
exposure levels (Matheson et al., 2005a).  The manner in which airway 
hyperresponsiveness and remodeling occur is thus affected by the intensity and 
duration of exposure.  For this reason, while some individuals may become 
sensitized to TDI in a relatively short period of time, for others sensitization may 
only develop following years of low-level exposure (Peters and Wegman, 1975). 
In the former case, neural sensitization may ultimately trigger an immune system 
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involvement, while in the latter case, development of a specific immune response 
can potentiate neural responsiveness. 
8.3.  Toluene  Diisocyanate Chronic Reference Exposure Level 
Study 
Study population 
Exposure method 
Continuity 
Duration 
Critical effects 
LOAEL 
NOAEL 
Time-adjusted exposure 
LOAEL uncertainty factor 
Subchronic uncertainty factor 
Interspecies uncertainty factor 
Toxicokinetic (UFa-k) 
Toxicodynamic (UFa-d) 
Intraspecies uncertainty factor 
Toxicokinetic (UFh-k) 
Toxicodynamic (UFh-d) 
Cumulative uncertainty factor 
Reference Exposure Level 
Diem et al., 1982 
277 adult male workers in TDI production 
Discontinuous whole-body inhalation 
exposure to 0.9 or 1.9 ppb 
8 hours per day, 5 days/week  
5 years 
Accelerated decline in FEV1 
13.5 µg/m
3 (1.9 ppb) 
6.4 µg/m
3 (0.9 ppb) 
2.285 µg/m
3 (6.4 * 10/20 *5/7) 
1 
√10 
1 
1 
10 
10 
300 
0.008 µg/m
3 (0.001 ppb) 
The chronic REL is a concentration at which adverse noncancer health effects 
would not be expected from chronic exposures (see Section 7 in the Technical 
Support Document (OEHHA, 2008)). 
The chronic REL is based on a prospective occupational study by Diem et al. 
(1982).  This study had several strengths over the other workplace investigations 
of TDI exposure, including minimal co-exposure to other irritating chemicals, 
extensive use of personal exposure monitoring devices, accounting of TDI-
sensitized workers in the cohort, and in particular, detailed longitudinal analysis 
of workers from the start of exposure in a new TDI production facility. 
In this five year longitudinal study by Diem et al. (1982), FEV1, Forced Percentual 
Expiratory Volume (FEV%), and FEF25-75% annual declines were significantly 
related (after controlling for smoking and atopic status) to TDI dose, where dose 
was measured by either: (a) two cumulative exposure categories, equivalent to a 
mean exposure of 0.9 or 1.9 ppb; or (b) two “time above 20 ppb” categories 
(division point = 0.19 months).  The accelerated decline in FEV1 occurred in the 
absence of workers with occupational asthma.  A NOAEL of 0.9 ppb (6.4 µg/m
3), 
the arithmetic mean of the non-smoking low-exposure group (≤68.2 ppb-months), 
was calculated by Hughes (U. S. EPA, 1995).  The LOAEL of 1.9 ppb is the 
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calculated arithmetic mean of the non-smoking high-exposure group.  Other 
longitudinal studies support the findings by Diem et al. that keeping 8-hr TWA 
TDI exposures below a range of about 1-2 ppb does not result in a measurable 
accelerated decline of pulmonary function. 
OEHHA’s noncancer TSD (OEHHA, 2008) calls for a 3-fold subchronic 
uncertainty factor for exposures from 8 to <12% of a lifetime.  The 5 year duration 
of the Diem study represents only about 7% of a worker’s lifetime of 70 years.  In 
consideration of the generally moderate but variable amount of time required for 
symptom manifestation, a subchronic UF of √10 was applied (rather than a UF of 
10).  Since the critical study is a human study, no interspecies adjustments were 
required. 
The toxicogenomics data for TDI and other diisocyanates show gene variants 
associated with increased sensitivity up to10-fold greater in workers developing 
diisocyanate-induced asthma.  Thus, an intraspecies toxicokinetic uncertainty 
factor (UFh-k) of 10 is applied. 
The intraspecies UFH-d (toxicodynamics) is used to account for 
pharmacodynamic variability among pregnant women and their fetuses and 
among infants, children, and adults.  Although the critical effect was in an adult 
worker population, the potential greater sensitivity for lung function impairment in 
the developing lungs of infants and children would support an intraspecies UFH-d 
of 10.  The total intraspecies UF would equal 100.  The cumulative UF of 300 
results in a chronic REL of 0.008 μg/m
3 (0.001 ppb). 
Application of an overall intraspecies UF of 100 is supported by the 
toxicogenomic data in Table 15, in which odds ratios for immune/inflammatory 
system genotype variation associations for increased susceptibility for 
diisocyanate-induced asthma fall in the range of 1.89 to 10.36.  However, these 
associations are for development of asthma rather than the critical effect of 
decreased lung function upon which the 8-hour and chronic RELs are based. 
There is currently no consensus on the threshold-sensitizing inhalation dose for 
TDI and some believe there may be no lower limit of exposure at which no 
workers will be sensitized (Tarlo and Liss, 2002).  This is due, in part, to the likely 
genetic predisposition for isocyanate-induced asthma at extremely low levels in 
some individuals (Suojalehto et al., 2011).  Sensitization to TDI can occur within 
weeks of first exposure, or after many years of exposure.  This would argue in 
favor of genetic predisposition for some individuals, rather than a concentration-
related correlation for onset of TDI-induced asthma.  Also, the role of peak 
exposures in workers (e.g., accidental spills) may be a factor in the onset of 
isocyanate-induced asthma. 
In the summarized longitudinal studies above, the level of TDI at which workers 
may become sensitized to TDI has not been as thoroughly investigated as the 
accelerated loss of FEV1.  Nevertheless, the data by Weill et al. (1981) indicate 
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that the NOAEL of 0.9 ppb for accelerated non-sensitized pulmonary function will 
also keep the prevalence of TDI-induced asthma very low.  Weill et al. (1981) 
showed that two of 12 men that became sensitized during the 5-year study had 
worked in jobs with low TDI exposure (TWA 1.6 ppb).  The other sensitized 
workers were exposed to higher TWA levels of ≥3.2 ppb TDI.  The investigators 
stratified the workers by cumulative exposures of <68.2 ppb-month and ≥68.2 
ppb-month (equivalent to a TWA of 0.9 and 1.9 ppb, respectively); it was unclear 
from the report which grouping the sensitized workers were in.  However, it 
appears likely that most of the sensitized workers, if not all, were assigned to the 
≥68.2 ppb-month group.  If that is true, then the NOAEL of 0.9 ppb for 
accelerated decrease in FEV1 should protect most individuals from diisocyanate­
induced sensitization.  The database as a whole supports this assumption. 
Supporting evidence for low prevalence of asthma at 0.9 ppb is provided by 
Musk et al. (1982) in the 5-year longitudinal study in which no indication of TDI-
induced sensitization was found in 107 workers exposed to 20-60 min peak 
exposures of 1.0-1.5 ppb (90
th percentile: 5.0 ppb).  Examination for sensitization 
and follow-up of workers leaving the industry was not as rigorous as that used for 
the Weill et al. study.  However, it was claimed by the authors that the 152 
workers that left before follow-up was due to high labor turnover in unskilled 
occupations and the reorganization of the industry, and likely not due to 
symptoms of sensitization. 
Ott et al. (2000) observed a decline in annual incidence of sensitization with 
improvement of environmental conditions.  The yearly incidence of sensitization 
was 1.1% before 1980, and 0.7% thereafter when 8-hr TWA TDI concentrations 
were reduced from ≥5.9 ppb to about 2.8 ppb. 
Other supportive evidence comes from cross-sectional or case-referent studies. 
Meredith et al. (2000) established a TWA exposure of 1.5 ppb (95% confidence 
interval 1.2-1.8) in a group of 27 workers that became sensitized primarily to TDI. 
Exposure above the median TDI exposure level of 1.125 ppb of a matched 
referent group increased the odds 3.2-fold of developing occupational asthma. 
Tarlo et al. (1997) found plants with at least one exposure above 5 ppb were 
more likely to have cases of isocyanate-induced asthma than companies in 
which exposures were kept below 5 ppb. 
For comparison, the U.S. EPA (1995) estimated a Reference Concentration of 
0.07 µg/m
3 also based on the Diem study.  The 10-fold difference in the U.S. 
EPA derivation and the chronic REL results from OEHHA’s use of intraspecies 
toxicodynamic and toxicokinetic UFs of 10, rather than 10, to address the 
respiratory susceptibility of children, and the differences in risk of diisocyanate­
induced asthma in workers based on genotype for a number of enzymes 
including GST, NAT, and epoxide hydrolase. 
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8.4.	  TDI as a Toxic Air Contaminant Especially Affecting Infants 
and Children 
Under Health and Safety Code Section 39669.5, OEHHA establishes and 
maintains a list of Toxic Air Contaminants (TACs) that may disproportionately 
impact infants and children.  OEHHA evaluates TACs for addition to this list when 
developing Reference Exposure Levels for TACs.  TDI was identified by the Air 
Resources Board as a toxic air contaminant in accordance with Section 39657(b) 
of the California Health and Safety Code (Title 17, California Code of 
Regulations, section 93001) (CCR, 2007).  TDI has been shown to cause 
asthmatic reactions in non-sensitized asthmatic adults in controlled exposure 
studies (Vogelmeier et al., 1991; Baur et al., 1994), and in non-sensitized 
children with asthma as well as asthma-like effects in children without asthma 
exposed acutely to the diisocyanate MDI in an accidental exposure (Jan et al., 
2008).  OEHHA considers asthma a disease that disproportionately impacts 
children, and thus chemicals that induce or exacerbate asthma are considered 
more impactful for children (OEHHA, 2001).  Animal models for TDI-induced 
asthma have produced TH2-dominated sensitization.  In humans during the first 
few years of life, the dominant TH2 response converts to a more cellular TH1 
immune response characteristic of the mature adult immune system.  Any delay 
or shift to a TH2 pattern during early life as a result of chemical stressors, 
including TDI, has been strongly associated with asthma.  In view of the potential 
of TDI to induce or exacerbate asthma and the differential impacts of asthma on 
children including higher prevalence rates, and in view of the rapid development 
of the lung during infancy, OEHHA recommends that TDI be identified as a TAC 
that may disproportionally impact children pursuant to Health and Safety Code 
Section 39669.5(c). 
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